HOME     SUBSCRIBERS     TRADE     PRODUCTS & SERVICES    
About Sharenet
Enter any share name or code:    

13-Nov-2018
(Official Notice)
17-Oct-2018
(Official Notice)
Shareholders are advised that the annual compliance report in terms of Section 13G (2) of the Broad- Based Black Economic Empowerment Amendment Act No.46 of 2013, as amended is available on Adcock Ingram website http://www.adcock.co.za/Content/pdf/BBBEE1_form_Oct_2018.pdf.
29-Aug-2018
(Official Notice)
Shareholders are advised of the following changes to Directors? responsibilities relating to the HR, Remuneration and Nominations Committee (?the Committee?), with effect from 28 August 2018:

* Ms Nompumelelo ?Mpumi? Madisa has been appointed as a member of the Committee;

* Mr Mpho Makwana will step down as the Chairman of the Committee and continue to serve as its member; and

* Ms Lulama Boyce has been appointed as the Chairperson of the Committee.



The Chairman of the Board will continue to chair the Committee when constituted as the Nominations Committee.
29-Aug-2018
(C)
Revenue from continuing operations for the year increased by 10% to R6.6 billion (2017: R6 billion) , gross profit grew by 14% to R2.6 billion (2017: R2.2 billion) and operating profit shot up by 21% to R819.5 million (2017: R677.3 million). Profit attributable to owners of the parent rose to R637.9 million (2017: 553.5 million). In addition, headline earnings per share from continuing operations was 26% higher at 387.7 cents per share (2017: 308.9 cents per share).



Dividend distribution

The board has declared a final dividend of 86 cents per share for the year ended 30 June 2018 out of income reserves. Total dividend distribution will therefore be 172 cents per share, an improvement of 24% compared to 2017.



Company prospects

The board expects trading conditions to remain difficult with constrained consumer spend and high levels of unemployment, but is confident in the equity and resilience of the broad portfolio of brands in the Group. The recent decline in the value of the Rand is of concern and against this background cost-control will be a focus in the year ahead.



Adcock Ingram is engaging constructively with the National Department of Health through the Pricing Committee on whether any short-term relief on SEP will be available.



The board remains committed in seeking additional affordable brands to augment its range of products and defend its position in the market. Expanding the non-regulated portfolio to limit the impact of the exchange rate and SEP environment remains a focus in this regard.
22-Aug-2018
(Official Notice)
Adcock Ingram will publish its Group Annual Financial Results for the year ended 30 June 2018 on the Stock Exchange News Service on Wednesday, 29 August 2018.



Shareholders are advised that following the publication of the results announcement, a conference call will be hosted by Mr Andy Hall, CEO and Ms Dorette Neethling, CFO. Interested parties are invited to dial in by 11:00 (South African Standard Time [SAST]), using the appropriate number from the list given below. You will be required to register with your name and company name, as you enter the call.
21-Aug-2018
(Official Notice)
Shareholders are accordingly advised that in the financial results for the year ended 30 June 2018, EPS from total operations is expected to be between 380 and 385 cents per share, (June 2017: 332.9 cents) and HEPS from total operations is expected to be between 380 cents and 390 cents per share, (June 2017: 312.6 cents). This represents an increase in EPS from total operations of between 14.1% and 15.7% and an increase in HEPS from total operations of between 21.6% and 24.8%.



Shareholders are also advised that in the financial results for the year ended 30 June 2018, EPS from continuing operations is expected to be between 380 and 385 cents per share, (June 2017: 308.9 cents) and HEPS from continuing operations is expected to be between 380 cents and 390 cents per share, (June 2017: 308.9 cents). This represents an increase in EPS from continuing operations of between 23.0% and 24.6% and an increase in HEPS from continuing operations of between 23.0% and 26.3%.



The financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors. Adcock Ingram is currently finalising its results for the financial year ended 30 June 2018, which are expected to be released on SENS on or about 29 August 2018, in which more comprehensive information will be provided.
04-Jul-2018
(Official Notice)
Shareholders are referred to the results of the Annual General Meeting (AGM) announcement released on the Stock Exchange News Service on 23 November 2017. Adcock Ingram further invites those shareholders who voted against the remuneration policy and the implementation thereof at the AGM (?dissenting shareholders?) to engage with the Company as follows:

1. a telephone conference has been arranged for Monday, 23 July 2018 from 15h00 to 16h00 (SA time);

2. all dissenting shareholders to confirm their participation to the Company Secretary by e-mail to ntando.simelane@adcock.com by no later than close of business on Friday, 20 July 2018. Dial-in details for the telephone conference will then be provided; and

3. dissenting shareholders are further invited to forward their concerns/questions on the remuneration policy and the implementation thereof in writing by email to ntando.simelane@adcock.com by close of business on Thursday, 19 July 2018.
13-Mar-2018
(Official Notice)
Shareholders are referred to the voluntary announcement released on the Stock Exchange News Service on 12 September 2017 regarding the acquisition of Genop Holdings (PTY) Ltd. (?Genop?). Adcock Ingram is pleased to announce that all conditions precedent, including regulatory approvals, have been met and the acquisition is now unconditional. Genop will operate as a separate company within the Adcock Ingram group, reporting into and managed within the Prescription Segment.
21-Feb-2018
(C)
Revenue for the interim period increased by 8% to R3.214 billion (2016: R2.985 billion), gross profit rose by 13% to R1.215 billion (2016: R1.074 billion), operating profit jumped 25% to R403.7 million (2016: R322.7 million), profit attributable to owners of the parent was higher at R320.3 million (2016: R280.9 million), while headline earnings per ordinary share from continuing operations grew by 33% to 192.6 cents per share (2016: 144.9 cents per share).



Dividend distribution

The Board has declared an interim gross dividend out of income reserves of 86 cents per share in respect of the six months ended 31 December 2017.



Company prospects

We are pleased with the quality of earnings, and the operational and strategic progress achieved. However, the operating environment remains challenging in South Africa, especially seen in the light of the recent disappointing SEP increase of 1.26% and ongoing financial pressure on consumers.



Nonetheless, the Group remains competitively positioned to defend and grow its brands and the Board remains committed in pursuing its objective of ensuring long-term growth to create shareholder value by expanding the product portfolio through partnership arrangements and acquisitions.



Changes to the Board

On 23 November 2017, Ms Nompumelelo Madisa was appointed as non-executive Director and a member of the Acquisitions Committee. On 29 January 2018 Mr Motty Sacks resigned as a non-executive Director, Chairman of the Audit Committee and member of various other committees.
20-Feb-2018
(Official Notice)
In accordance with paragraph 3.59 of the Listings Requirements of the JSE Limited, shareholders are advised that Ms Jenitha John, has been appointed as the Chairperson of the Audit Committee with effect from 20 February 2018. Ms John was appointed as an independent non-executive director of Adcock Ingram on 24 May 2017 and as a member of the Audit and Risk and Sustainability Committees. The Board of Directors wishes Ms John well in her new role.

16-Feb-2018
(Official Notice)
Adcock Ingram will publish its interim financial results on Wednesday, 21 February 2018 on SENS, for the six-month period ended 31 December 2017. Shareholders are advised that following the publication of the interim results announcement, a conference call will be hosted by Mr Andy Hall, Chief Executive Officer and Ms Dorette Neethling, Chief Financial Officer. Interested parties are invited to dial in by 11:00 (South African Standard Time [SAST] - GMT +02:00), using the appropriate number from the list given below. You will be required to register before entering the call. A short question and answer session will follow the oral presentation.



Live Call Access Numbers for Participants

Country and Access Number

Johannesburg (Telkom) - 011 535 3600

South Africa (Toll Free) - 0 800 200 648

Johannesburg (Neotel) - 010 201 6800

Other Countries (Telkom) - +27 10 201 6800

Other Countries (Neotel) - +27 11 535 3600 UK - 0 333 300 1418

USA and Canada - 1 508 924 4326



Playback Access Numbers - Playback Code: 10128



Country and Access Number

South Africa - 010 500 4108

UK - 0 203 608 8021

Australia - 073 911 1378

USA - 1 412 317 0088

International - +27 10 500 4108
13-Feb-2018
(Official Notice)
In the Company?s trading statement released on the Stock Exchange News Service (SENS) on 16 January 2018 (initial trading statement), shareholders were advised that the Company expected to report increases in headline earnings per share (HEPS) and earnings per share (EPS) for the six-month period ended 31 December 2017 of not less than 27% (40 cents) and 12% (20 cents) respectively, compared to the previous corresponding reporting period. A more defined range of earnings was also to be provided when such information became available.



Shareholders were also advised in the initial trading statement that, during the six-month period ended 31 December 2016 (previous corresponding reporting period), certain non-trading capital profits arose on the disposal of the Group?s business in India during October 2016.



Having regard to the above, shareholders are advised that the Company expects HEPS for the six-month period ended 31 December 2017 to reflect an increase of between 27% and 30%, being 188.6 cents and 193.6 cents, compared to the previous corresponding reporting period (December 2016: 148.6 cents). EPS for the six-month period ended 31 December 2017is expected to reflect an increase of between 12% and 15% being 188.9 cents and 193.9 cents (December 2016: 168.9 cents).



Adcock Ingram is currently finalising its results for the six-month period ended 31 December 2017, which are expected to be released on SENS on or about 21 February 2018, in which more comprehensive details will be provided.



The financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors.

29-Jan-2018
(Official Notice)
Adcock?s shareholders were notified that Mr Michael ?Motty? Sacks has tendered his resignation as a non-executive director, Chairman of the Audit Committee and member of the Risk and Sustainability, HR, Remuneration and Nominations, as well as the Acquisitions Committee with effect from Monday, 29 January 2018.
16-Jan-2018
(Official Notice)
Shareholders are reminded that the earnings per share (EPS) and headline earnings per share (HEPS) for the six-month period ended 31 December 2016 (previous corresponding reporting period) was 168.9 cents and 148.6 cents respectively. The difference of 20.3 cents substantially arose through certain non-trading capital profits on the disposal of the Group?s business in India during October 2016.



Shareholders are advised that the company expects HEPS for the six-month period ended 31 December 2017 to be not less than 27% (40 cents) higher than the previous corresponding reporting period. It is further expected that EPS for the six-month period ended 31 December 2017 will not be less than 12% (20 cents) higher, relative to the previous corresponding reporting period.



Adcock Ingram is in the process of finalising the results for the six-month period ended 31 December 2017 and a more defined range of both EPS and HEPS (as required by the JSE Listings Requirements) will be announced in a further Trading Statement on SENS in due course.
24-Nov-2017
(Official Notice)
Shareholders are advised that at the annual general meeting (?AGM?) held yesterday, 23 November 2017, convened in terms of the notice of the AGM forming part of the integrated report, all the ordinary and special resolutions proposed at the AGM were passed by the requisite majority of votes.



Remuneration policy and implementation report

The remuneration policy and the implementation report were both voted against by shareholders exercising 25% or more of the voting rights exercised. In accordance with paragraph 3.91 of the JSE Ltd. Listings Requirements, the Company now invites those shareholders who voted against the remuneration policy and the implementation report (?dissenting shareholders?) to engage with the Company and to raise any questions or concerns they might have. Submissions should please be emailed to the Company Secretary, at ntando.simelane@adcock.com, by no later 28 February 2018. Should dissenting shareholders wish to engage with the Company in person they may likewise email the Company Secretary with their request.



Changes to the board

In accordance with paragraph 3.59 of the Listings Requirements of the JSE Ltd., shareholders are advised that Ms Nompumelelo Madisa has been appointed as non-executive director on the Adcock board of directors with effect from 23 November 2017. In addition to being a member of the board, Ms Madisa will also serve as a member of the Acquisitions Committee.



31-Oct-2017
(Official Notice)
Shareholders are advised that the annual compliance report in terms of Section 13G(2) of the Broad- Based Black Economic Empowerment Amendment Act No.46 of 2013, as amended is available on Adcock Ingram website www.adcock.co.za.





26-Oct-2017
(Official Notice)
In respect of the audited results for the financial year ended 30 June 2017, shareholders are advised that the annual financial statements were distributed to shareholders on Thursday, 26 October 2017 and contain no modifications to the audited results which were published on SENS on Friday, 25 August 2017. The electronic version of the annual financial statements can be found on the company?s website www.adcock.com.



Notice of the annual general meeting (AGM)

Notice is hereby given that the AGM of Adcock Ingram will be held at the company?s premises, 1 New Road, Midrand, Gauteng on Thursday, 23 November 2017 at 09h00 to transact the business as indicated in the notice forming part of the annual financial statements.



Salient dates

*Record date to determine which shareholders are entitled to receive the notice of the AGM - 20 October 2017

*Last day to trade in order to be eligible to attend and vote at the AGM - 14 November 2017

*Record date to determine which shareholders are entitled to participate and vote at the AGM - 17 November 2017

*Forms of proxy for the AGM to be lodged with the company?s transfer secretaries, Computershare Investor Services (Pty) Ltd. by no later than 09h00* - 21 November 2017

*any proxies not lodged by this time must be handed to the chairperson of the AGM immediately prior to such proxy exercising his/her right to vote at the AGM.
12-Sep-2017
(Official Notice)
Adcock Ingram is pleased to announce that it has concluded a Share Purchase Agreement to acquire 100% of the shares of Genop Holdings (Pty) Ltd. and its subsidiaries ('Genop' or the 'Business') for a confidential purchase price, payable in cash, (the 'Genop Acquisition').



Genop is a highly specialised instrument, surgical and pharmaceutical products company focussed on the ophthalmic, optometry, skincare, aesthetic and plastic surgery segments in Southern Africa, with historic revenue of approximately R400 million per annum.



Genop owns and markets the well-known Epi-max branded range of consumer products and holds exclusive distribution rights for leading international brands in the segments/categories in which it operates.



The board of directors of Adcock Ingram considers the Genop Acquisition to present an attractive investment opportunity -



Rationale for the Genop Acquisition:

*Acquisition of the Epi-max brand and range of products. The brand is well established with strong awareness among consumers and dermatologists. The brand has potential for further line extensions.

*Acquisition of one of the largest suppliers of optical instruments in South Africa. Genop has been one of the market leaders in this space for over 90 years.

*Diversification. Genop?s product portfolio has very little overlap with Adcock Ingram?s existing portfolio and allows for diversification into non-SEP (single exit price) regulated products in specialised areas or therapeutic categories, such as pharmaceuticals (OTC dermatology ? Epi-max; ophthalmic products ? contact lens solution), ophthalmics (lenses, diagnostic and surgical equipment, and consumables), dermatology (dermal fillers, medical cosmetics, aesthetic lasers) and plastic surgery (breast implants, scar therapy and compression garments).



The Genop Acquisition is not a categorized transaction in terms of the JSE Ltd. Listings Requirements. Accordingly, no shareholder approval is required and this announcement is published voluntarily.



The Genop Acquisition is subject to regulatory approvals and other conditions precedent typical for a transaction of this nature. A further announcement regarding the implementation of the Genop Acquisition will be made at the appropriate time.

25-Aug-2017
(C)
Revenue from continuing operations increased by 7% to R6 billion (2016: R5.6 billion). Gross profit rose by 10% to R2.2 billion (2016: R2 billion). Operating profit shot up by 22% to R677.3 million (2016: R553.2 million). Profit attributable to owners of the parent soared to R553.5 million (2016: R168.8 million). Furthermore, headline earnings per share from continuing operations was 37% higher at 308.9 cents per share (2016: 226.1 cents per share).



Dividend distribution

The Board has declared a final dividend of 76 cents per share for the year ended 30 June 2017 out of income reserves. Total dividend distributions for the year will therefore be 139 cents per share an increase of 34% compared to 2016.



Prospects

The Adcock Ingram Group, like other corporates in South Africa, enters a new financial year presently characterised by a range of challenges which include, inter alia, low economic growth, volatile currency conversion rates, rising unemployment, political uncertainty and several other local and global spheres of instability.



Notwithstanding these national and international realities, the board takes comfort from the fact that today, the Adcock Ingram Group is a well-managed, well capitalised and profitable group enterprise, with inspired and motivated teams throughout the organisation operating in a relatively defensive sector of the economy.



The strategy of the Group remains the pursuit of additional sector opportunities, by acquisition or partnership, to expand the Group's product portfolio and to leverage and rationalise the Group capacity for further growth, particularly in less regulated product classes, preferably without the immediate need for material capital expenditure and infrastructure.



The experience gained over the past three years of focused remedial activity, is not materially different from the protective nature of conducting business in today's economic circumstances and the Board remains assured by the Group's capable management and is cautiously confident in the prospects for sustainability for the year ahead, subject always to there being no unexpected material economic and/or political disruptions arising.

22-Aug-2017
(Official Notice)
Adcock Ingram will publish on SENS on Friday 25 August 2017 the Group Financial Results for the year ended 30 June 2017. Shareholders are advised that following the publication of the results announcement, a conference call will be hosted by Mr Andy Hall, Chief Executive Officer and Ms Dorette Neethling, Chief Financial Officer. Interested parties are invited to dial in by 11:00 (South African Standard Time [SAST] - GMT +02:00), using the appropriate number from the list given below. You will be required to register with your name and company name, as you enter the call. A short question and answer session will follow the oral presentation.



Live Call Access Numbers for participants are:

South Africa - Toll Free : 0 800 203 599

Other Countries - International : +27 11 535 3600

Other Countries - International : +27 10 201 6800

South Africa - Johannesburg Telkom : 011 535 3600

South Africa - Johannesburg Neotel : 010 201 6800

USA and Canada - Toll Free : 1 855 481 5362

UK - Toll Free : 0 808 162 4061



Playback Access Numbers - Playback Code: 15944

South Africa - Telkom : 011 305 2030

Other Countries - International Toll : +27 11 305 2030

USA and Canada - Toll Free : 1 855 481 5363

UK - Toll Free : 0 808 234 6771
21-Aug-2017
(Official Notice)
Adcock?s shareholders are hereby notified that Dr Brian Joffe has tendered his resignation as a non-executive director and Chairman of the Acquisitions Committee from Adcock with immediate effect. The board of directors of Adcock will make an announcement regarding the chairmanship of the Acquisitions Committee in due course.
17-Aug-2017
(Official Notice)
Shareholders are advised that in the financial results for the year ended 30 June 2017, EPS is expected to be between 330 and 333 cents per share, (June 2016: 101.4 cents) and HEPS, is expected to be between 310 cents and 313 cents per share, (June 2016: 228.7 cents). This represents an increase in HEPS of between 36% and 37%.



In an earlier trading statement released on SENS on 24 July 2017, shareholders were advised that in the previous corresponding reporting period, losses of R200 million on the disposal of certain discontinued operations were accounted for, adversely impacting the EPS in that year. The comparable increase in HEPS for the current reporting period arises in the normal course of trade and business.



The financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors.



Adcock Ingram is currently finalising its results for the financial year ended 30 June 2017, which are expected to be released on SENS on or about 25 August 2017, in which more comprehensive information will be provided.



24-Jul-2017
(Official Notice)
While the information provided in this trading statement will indicate a very satisfying improvement in both earnings per share (?EPS?) and headline earnings per share (?HEPS?) for the year under review, for a proper appreciation of the relative annual performance, shareholders should take into account certain losses incurred in the 2016 year and certain contributory profits in this year, that would in the normal course, be excluded from the comparable measurements of the Group?s customary trading operations.



With regard thereto, shareholder attention is drawn to the losses incurred on discontinued operations of R200 million for the year ended 30 June 2016 and the profits of R41 million realized in the first six months of the 2017 financial year on the disposal of the Group?s Indian selling and distribution business, both of these amounts having relevance to the concluding guidance hereunder.



The EPS and HEPS reported for the year ended 30 June 2016, was 101.4 cents and 228.7 cents respectively. Taking the above caveats into account, the Company expects EPS and HEPS for the year ended 30 June 2017 to be not less than 324.5 cents and 297.3 cents respectively, reflecting an increase in the case of EPS of not less than 220% and in the case of HEPS, an increase of not less than 30%.



A more defined range and explanation of both EPS and HEPS will be announced in a further trading statement on SENS in due course.
15-Jun-2017
(Official Notice)
Shareholders are advised that a settlement has been reached in respect of a complaint referral to the Competition Tribunal by the Competition Commission, alleging that Adcock Ingram and other respondents (collectively, ?the respondents?) had possibly contravened section 13A(3) of the Competition Act 89 of 1998, as amended, by pre-implementation of a merger.



In order to avoid protracted and expensive litigation, the respondents have, without admitting guilt, reached a settlement with the Competition Commission. The settlement has been confirmed by the Competition Tribunal.



As part of the settlement, the respondents have agreed to pay a settlement amount of R2 million and to develop, implement and monitor a competition law compliance programme for senior management and directors.
24-May-2017
(Official Notice)
Shareholders are referred to the announcement released on the Stock Exchange News Service this morning, 24 May 2017, regarding, inter alia, the appointment of Ms Lulama Boyce as a Non-Executive Director of the Company and a member of the Audit Committee and the HR, Remuneration and Nominations Committee.



Shareholders are advised that the abridged curriculum vitae of Ms Boyce erroneously referred to her position as Deputy Head of the Commercial Accounting Department at the University of Johannesburg. In fact, Ms Boyce is the Subject Head, and not the Deputy Head, of this Department.
24-May-2017
(Official Notice)
Shareholders are advised of the following changes to the Board and Executive Directors? responsibilities at Adcock Ingram, each with immediate effect:

a) Ms Lulama Boyce has been appointed as Non-Executive Director of the Company and a member of the Audit Committee and the HR, Remuneration and Nominations Committee.

b) Ms Jenitha John has been appointed as Non-Executive Director of the Company and a member of the Audit Committee and Risk - Sustainability Committee.

c) The Board further appointed Mr Andrew Hall and Ms Dorette Neethling, in their respective capacities as the CEO and CFO, as members of the Risk - Sustainability Committee in accordance with the recommendations of the King IV Report on Corporate Governance.
24-Feb-2017
(Official Notice)
Shareholders are advised that following the announcement by the South African Minister of Finance on 22 February 2017, the dividend withholding tax rate has been increased from 15.0% to 20.0%, effective 22 February 2017. Further to the announcement released on the Stock Exchange News Service of the JSE Ltd. on 22 February 2017, of the unaudited results of the Company for the six-month period ended 31 December 2016, shareholders are requested to refer to the updated dividend declaration paragraph included below:



Cash dividend

The Board has declared an interim gross dividend out of income reserves of 63 cents per share in respect of the six months ended 31 December 2016. The South African dividend tax ("DT") rate is 20% and the net dividend payable to shareholders who are not exempt from DT is 50.40 cents per share. Adcock Ingram currently has 175 748 048 ordinary shares in issue of which 149 905 089 qualify for ordinary dividends. The income tax reference number is 9528/919/15/3.



The salient dates for the distribution are detailed below:

* Last date to trade cum distribution : Tuesday, 14 March 2017

* Shares trade ex distribution : Wednesday, 15 March 2017

* Record date : Friday, 17 March 2017

* Payment date : Monday, 20 March 2017
22-Feb-2017
(C)
Revenue increased by 11% to R2.985 billion (2015: R2.684 billion), gross profit rose by 11% to R1.074 billion (2015: R971.3 million), operating profit jumped by 35% to R322.7 million (2015: R238.3 million), profit attributable to owners of the parent soared to R280.9 million (2015: R166.7 million), while headline earnings per ordinary share from continuing operations grew by 52% to 144.9 cents per share (2015: 95.1 cents per share).



Dividend

The Board has declared an interim gross dividend out of income reserves of 63 cents per share in respect of the six months ended 31 December 2016.



Prospects

The Adcock Ingram Group is today a well-managed, reliable, reputable and well capitalised pharmaceutical manufacturer, supplier and distributor in South Africa, which is well placed to continue its immediate past trend of performance, fulfilling its potential to maintain its current growth path.



Given the Group's healthy cash resources, management and the Board will maintain the intention to expand the Group's product portfolio, through partnership arrangements, acquisition or otherwise, particularly in non-regulated product classes.



Shareholders can be assured of the Group's intention to continue its effort to enhance the equity of the Company's products and brands, build its customer relationships and maintain its service levels within each of the operating divisions.
17-Feb-2017
(Official Notice)
Adcock Ingram will publish its interim financial results for the six month period ended 31 December 2016 on 22 February 2017, on SENS. Shareholders are advised that following the publication of the interim results announcement, a conference call will be hosted by Mr Andy Hall, Chief Executive Officer and Ms Dorette Neethling, Chief Financial Officer. Interested parties are invited to dial in by 11:00 (South African Standard Time [SAST] - GMT +02:00), using the appropriate number from the list given below. You will be required to register before entering the call. A short question and answer session will follow the oral presentation.
14-Feb-2017
(Official Notice)
In an earlier trading statement released on SENS on 19 January 2017, shareholders were advised that the Company expected to report increases in earnings per share (EPS) and headline earnings per share (HEPS) from total operations of not less than 60% and 40% respectively, compared to the previous corresponding reporting period. A more defined range of earnings was also to be provided when such information became available.



Shareholders were also advised earlier, that during the six-month period ended 31 December 2016, a non- recurring capital profit arose as a result of the disposal of the Group?s Indian business and certain non-recurring IFRS 2 costs, were incurred in the previous corresponding reporting period.



Having regard to the above, shareholders are advised that EPS for the period under review, will reflect an increase of between 65% and 71%, being 164 and 170 cents per share, compared to the previous corresponding reporting period (December 2015: 99.6 cents). HEPS for the period under review, will reflect an increase of between 45% and 49% being, 145 cents and 149 cents per share (December 2015:99.8 cents).



The financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors.



Adcock Ingram is currently finalising its results for the six-month period ended 31 December 2016, which are expected to be released on SENS on or about 22 February 2017, in which more comprehensive details will be provided.





19-Jan-2017
(Official Notice)
In terms of the JSE Ltd. (?JSE?) Listings Requirements, companies are required to provide guidance to the market when they are satisfied that a reasonable degree of certainty exists that the financial results for the current reporting period will differ by at least 20% from the results of the previous corresponding reporting period. The earnings per share (?EPS?) and headline earnings per share (?HEPS?) reported for the six-month period ended 31 December 2015 (?previous corresponding reporting period?) was 99.6 cents and 99.8 cents respectively.



Adcock Ingram is currently finalising its results for the six-month period ended 31 December 2016. Shareholders are advised that during this period, certain non-recurring capital profits arose as a result of the disposal of the Group?s Indian business. There were also certain non-recurring IFRS 2 charges in the previous corresponding reporting period.



Accordingly, shareholders are advised that the company expects EPS for the six-month period ended 31 December 2016 to be not less than 60% (60 cents) higher, relative to the previous corresponding reporting period. It is further expected that HEPS for the six-month period ended 31 December 2016 will be not less than 40% (40 cents) higher than the previous corresponding reporting period.



A more defined range for both EPS and HEPS as required by the JSE Listings Requirements will be announced in a further trading statement in due course.



The financial information on which this trading statement is based has not been reviewed and reported on by the Company?s external auditors.



07-Dec-2016
(Official Notice)
Shareholders are advised that, at the announcement of the company?s financial results for the year ended 30 June 2016, it was noted that Adcock Ingram had concluded a share purchase agreement with Dannex Ltd. (?Dannex?), in terms of which the company agreed to dispose of 53% of its interest in Ayrton Drug Manufacturing Ltd. (?Ayrton?) to Dannex(?Transaction?).



The Transaction was subject to approval by the Ghana Securities and Exchange Commission (?Commission?) and an application by Dannex to the Commission on 8 August 2016 sought to exempt Dannex from making a general offer to all remaining Ayton shareholders.



The Commission subsequently granted Dannex approval to proceed with the Transaction, subject to the fulfilment of certain conditions. Adcock Ingram announces that Dannex has since complied with all the conditions precedent and the transaction closed on 30 November 2016. The company has concluded a voting pool agreement with Dannex, in relation to the 25.1% interest Adcock Ingram retains in Ayrton.



28-Nov-2016
(Official Notice)
Shareholders are referred to the announcement released on the Stock Exchange News Service on Thursday, 24 November 2016 regarding, inter alia, the appointment of Dr Claudia Manning and Mr Lindsay Ralphs to the Adcock board of directors.



In addition to their responsibilities as non-executive directors, Dr Manning and Mr Ralphs shall serve as members of the Risk and Sustainability Committee and Acquisitions Committee respectively.







24-Nov-2016
(Official Notice)
Shareholders are advised that at the annual general meeting (?AGM?) held today, 24 November 2016, convened in terms of the notice of AGM forming part of the integrated report, all the ordinary and special resolutions proposed at the AGM were passed by the requisite majority of votes.



Changes to the board

Shareholders are advised that Dr Claudia Manning and Mr Lindsay Ralphs have been appointed as non-executive directors on the Adcock board of directors effective immediately.



Mr Roshan Morar

Mr Morar retired by rotation in accordance with the Company?s MOI and was eligible and suitable for re-election but has decided not to offer himself for re-election.

14-Oct-2016
(Official Notice)
Adcock shareholders are referred to the announcement released on the Stock Exchange News Service of the JSE Ltd. on 6 April 2016, regarding its wholly-owned subsidiaries, Adcock Ingram International (Pty) Ltd. and Adcock Ingram Healthcare (Pty) Ltd. (?Sellers?) entering into definitive agreements with Samara Capital Partners Fund II Ltd. for the disposal of their entire 100% shareholding in Adcock Ingram Healthcare Private Ltd. (?Adcock Healthcare?) which operates its Indian pharmaceutical marketing and selling business (?Transaction?).



Finalisation of the Transaction

Adcock can confirm that all conditions precedent to the Transaction have been fulfilled or waived and the closing date of the Transaction is Friday, 14 October 2016.



The Regulatory Services Business has been separated from Adcock Healthcare as of 31 August 2016 and is now housed in a new subsidiary named Relicare Tech Services Private Ltd.



Sale consideration

The total sale consideration received by the Sellers pursuant to the Transaction is R407 million on the basis as set out below:

*Proceeds from buy-back of shares in Adcock Healthcare of INR400 million (R85 million) which was a condition precedent to the Transaction; and

*Disposal proceeds of INR1,522 million (R322 million).





30-Sep-2016
(Official Notice)
With regard to the audited results for the financial year ended 30 June 2016, shareholders are advised that the annual financial statements were distributed to shareholders today, Friday, 30 September 2016 and contain no modifications to the audited results which were published on SENS on Friday, 26 August 2016. The electronic version of the annual financial statements can be found on the Company?s website www.adcock.com.



Notice of the annual general meeting

Notice is hereby given that the annual general meeting of Adcock Ingram shareholders will be held at the company?s offices, 1 New Road, Midrand, Gauteng on Thursday, 24 November 2016 at 09h00 to transact the business as indicated in the annual general meeting notice attached to the annual financial statements.



Salient dates

*Record date to determine which shareholders are entitled to receive the notice of annual general meeting - Friday, 23 September 2016

*Last day to trade in order to be eligible to attend and vote at the annual general meeting - Tuesday, 15 November 2016

*Record date to determine which shareholders are entitled to participate and vote at the annual general meeting - Friday, 18 November 2016

*Forms of proxy for the annual general meeting to be lodged with the company?s transfer secretaries, Computershare Investor Services (Pty) Ltd. by no later than 09h00* - Tuesday, 22 November 2016

*any proxies not lodged by this time must be handed to the chairperson of the annual general meeting immediately prior to the annual general meeting.
26-Aug-2016
(C)
Revenue for the year increased to R5.6 billion (2015: R5.2 billion). Gross profit rose to R2 billion (2015: R1.9 billion), operating profit climbed to R553.2 million (2015: R499.1 million), profit attributable to owners of the parent from continuing operations decreased to R168.8 million (2015: R197.9 million), while headline earnings per ordinary share from continuing operations climbed to 226.1 cents per share (2015: 198.7 cents per share).



Dividend

The Board has declared a final gross dividend out of income reserves of 54 cents per share in respect of the year ended 30 June 2016.



Prospects

The successful restructuring of the business over the past two years has resulted in a substantially cleansed, well controlled commercial platform, with a broad product range, in most cases, enjoying growing market support, but more importantly, having a re-energised, incentivised and informed management team.



Stakeholders will nevertheless be aware of the potential economic challenges that could lie ahead and the general consequences arising therefrom. Such circumstances could well have an effect on future sales volumes and profitability. Continued effort will however be invested, not only to enhance the quality and efficacy of our products, but to build and enhance our customer relationships and sustain our service levels within each of the operating divisions.



Given the healthy cash generation in this and in prior periods, the Group now has significant resources available for further growth and development. Management and the Board will maintain its focus on expanding the Group?s product portfolio, particularly in non-regulated areas through acquisitions and/or partnerships.
25-Aug-2016
(Official Notice)
Shareholders are advised that the company?s current Group Human Capital Executive, Ms Basadifeela Letsoalo, has been appointed Executive Director: Human Capital and Transformation, effective immediately.



19-Aug-2016
(Official Notice)
Adcock Ingram is currently finalising its results for the year ended 30 June 2016, which are expected to be released on SENS on or about 26 August 2016.



In this regard, shareholders are advised that headline earnings per share (HEPS) from total operations are likely to be between 227.2 cents and 228.9 cents per share (between 41.9% and 43.0%) higher than the 160.1 cents per share reported for the year ended 30 June 2015.

For a better appreciation of the earnings guidance herein, basic earnings per share and headline earnings per share from total operations, continuing operations and discontinued operations are provided below:



Total operations

Basic earnings per share - 98.4 ? 101.6; 117.2; (16.0%) ? (13.3%)

Headline earnings per share - 227.2 ? 228.9; 160.1; 41.9% - 43.0%



Continuing operations (Note 1)

Expected 30 June 2016 (cents), Reported 30 June 2015 (cents) and Change

Basic earnings per share - 222.6 ? 223.7 204.2 9.0% - 9.5%

Headline earnings per share - 225.1 ? 226.2 198.7 13.3% - 13.8%



Note 1

Basic and headline earnings from continuing operations have been adversely impacted by a once-off IFRS 2 charge of R20.8 million related to the B-BBEE scheme implemented in July 2015.



Discontinued operations (Note 2)

Expected 30 June 2016 (cents), Reported 30 June 2015 (cents) and Change

Basic loss per share - (124.2) ? (122.1) (87.0) (42.8%) ? (40.3%)

Headline earnings/(loss) per share - 2.1 ? 2.7 (38.6) 105.4% - 107.0%



Note 2

The basic loss from discontinued operations (including India and Ghana) has been impacted by impairments of R208 million recorded against investments categorised and treated as assets held-for-sale in terms of IFRS, compared to impairments of R81.8 million provided on the assets in the previous year.



In accordance with IFRS, amortisation and depreciation of the held-for-sale Indian assets were suspended from the start of the current financial year. The operating performance of the discontinued operations is therefore inflated in the current year when compared to the prior year. For a more meaningful comparison of the discontinued operations, depreciation and amortisation in the current year would have amounted to R45 million, if it had been provided for on the same basis as in 2015.
19-Aug-2016
(Official Notice)
Adcock Ingram will announce its financial results for the year ended 30 June 2016 on 26 August 2016, on SENS. Shareholders are advised that following the results announcement, a conference call will be hosted by Mr Andy Hall, Chief Executive Officer and Ms Dorette Neethling, Chief Financial Officer. Interested parties are invited to dial in by 11:00 (South African Standard Time (SAST) - GMT +02:00), using the appropriate number from the list given below. You will be required to register before entering the call. A short question and answer session will follow the oral presentation.
15-Jun-2016
(Official Notice)
Adcock Ingram?s shareholders are notified that Mr David Cleasby has tendered his resignation as an Adcock Ingram non-executive director and a member of the Risk and Sustainability Committee with immediate effect.



Mr Cleasby?s resignation comes after the successful unbundling of Bidcorp from Bidvest and his subsequent resignation from Bidvest.
06-Apr-2016
(Official Notice)
24-Feb-2016
(C)
Revenue for the interim period from continuing operations increased to R2.758 billion (2014: USD2.583 billion). Gross profit rose by 11% to R1 billion (2014: R904.7 million), operating profit was higher at R250.4 million (2014: R226.9 million), while profit attributable to owners of the parent jumped to R166.7 million (2014: R141.9 million). Furthermore, headline earnings per ordinary share from continuing operations grew by 5% to 98.6 cents per share (2014: 93.6 cents per share).



Dividend

The Board has declared an interim gross dividend out of income reserves of 50 cents per share in respect of the six months ended 31 December 2015.



Prospects

During calendar year 2015 and particularly during the period under review, the Group continued to make progress in restoring its status and regaining the respect of the broader South African pharmaceutical market. The trend of improvement in the Group?s operating performance, in this and immediately past periods, bears testimony to the beneficial outcome arising from the refocused effort of management under the divisional restructure.



While the improvement in profits during the subject period would suggest a continuing level of growth going forward, stakeholders will be acutely aware of the economic challenges that lie ahead. Recent increases in interest rates, consequential inflation, continued under-recovery of currency losses under government?s SEP reimbursement model and the potential further decline in disposable incomes, will surely have an effect on future sales volumes and profitability.



Notwithstanding these direct challenges, continued effort will be invested to enhance the quality and efficacy of brands, build customer relationships and maintain service levels within each of the operating divisions. The Group provides an excellent range of products into the market and management will continue to diligently apply themselves to maximise opportunities for optimal achievement. Concurrently with normal trading activities, there is a purposeful process in place to seek to expand the Group?s non-regulated product portfolio, through partnerships and acquisitions.
23-Feb-2016
(Official Notice)
Shareholders are referred to the announcement released on the Stock Exchange News Service on 11 November 2015 in which they were advised that Current Group Financial Executive, Ms Dorette Neethling, had been appointed Acting Chief Financial Officer. Shareholders are advised that Ms Neethling has been appointed to the board as an executive director and Chief Financial Officer, with immediate effect.
23-Feb-2016
(Official Notice)
Adcock will announce its interim results for the six month period ended 31 December 2015 on 24 February 2016, on SENS. Shareholders are advised that a conference call will be hosted by Mr Andy Hall , CEO and Ms Dorette Neethling, Acting CFO, following the results announcement. Interested parties are invited to dial in by 11:00 (South African Standard Time (SAST) - GMT +02:00) using the appropriate number from the list given below. You will be required to register before entering the call. A short question and answer session will follow the oral presentation.



Live Call Access Numbers For Participants are:

*Other Countries - International: +27 11 535 3600

*Other Countries - International: +27 10 201 6800

*South Africa - Johannesburg Telkom: 011 535 3600

*South Africa - Johannesburg Neotel: 010 201 6800

*South Africa - Toll-Free: 0 800 200 648

*UK - Toll-Free: 0808 162 4061



Playback Access Numbers - Playback Code: 45239

*Other Countries - International: +27 11 305 2030

*South Africa: 011 305 2030

*UK - Toll Free: 0 808 234 6771

*UK and Canada ? Toll Free: 1 855 481 5363







02-Feb-2016
(Official Notice)
Shareholders are advised of the following board committees? changes at Adcock Ingram, all of which are with immediate effect:

*Mr Clifford Raphiri, the non-executive chairman of the board, will relinquish his chairmanship of the HR, Remuneration and Nominations Committee, but will remain a member of this committee;

*Mr Mpho Makwana will relinquish his membership of the Risk and Sustainability Committee and assume chairmanship of the HR, Remuneration and Nominations Committee;

*Mr David Cleasby will assume membership of the Risk and Sustainability Committee; and

*The chief financial officer will no longer be a member of the Social Ethics and Transformation Committee.



19-Nov-2015
(Official Notice)
Shareholders are advised that at the annual general meeting ("AGM") held on 19 November 2015, convened in terms of the notice of AGM forming part of the annual financial statements, all the ordinary and special resolutions proposed at the AGM were passed by the requisite majority of Shareholders, as follows:

*Number of shares voted - 147 618 662

*Total issued share capital - 175 748 048

*Shares voted disclosed as a percentage in relation to the total issued share capital - 84%
11-Nov-2015
(Official Notice)
Shareholders are advised of the following board changes at Adcock Ingram, effective immediately:

* Mr Clifford Raphiri, the company?s current lead independent director, has been appointed Non-Executive Chairman, with Mr Brian Joffe assuming the role of Deputy Chairman;

* Mr Kevin Wakeford has resigned as Chief Executive Officer, and the company?s Deputy Chief Executive Officer and Chief Financial Officer, Mr Andrew Hall, has been appointed Chief Executive Officer. Mr Wakeford will remain with the company for a three-month phase out period;

* Current Group Financial Executive, Ms Dorette Neethling, has been appointed Acting Chief Financial Officer. A formal process is underway to identify suitable candidates, with a view to making a permanent appointment to the position; and

* Mr Lindsay Ralphs has resigned as a Non-executive Director and has been replaced by Mr David Cleasby.



Changes will be made to the various board committees and shareholders will be informed of these changes in due course.



Shareholders are referred to the media release below, for further information.



Media release

Adcock Ingram positions leadership structure to pursue growth

Adcock Ingram has announced changes to and the reorganisation of its board to ensure the successful, long-term continuity of the strategic changes that have been implemented within the company over the last two years.



The operating structure has already been aligned with the new strategic direction of the company, the major brands are showing good growth and the focus on customers, products and service has shown pleasing results. The company is now well positioned for its next phase of growth.



To ensure an enhanced focus on this next phase of the company?s development, and effective immediately, Clifford Raphiri, the current lead independent director, will take over from Brian Joffe as Chairman. Brian is assuming the role of Deputy Chairman allowing him to assist the executive team with its strategic growth initiatives.



Kevin Wakeford has resigned as Chief Executive Officer and has been replaced by the current Deputy Chief Executive Officer, Andy Hall. Kevin will re-join Bidvest Industrial Holdings in a senior management role after a phase out period of three months.
28-Sep-2015
(Official Notice)
With regard to the audited results for the financial year ended 30 June 2015, shareholders are advised that the annual financial statements were distributed to shareholders today, Monday, 28 September 2015, and contain no modifications to the audited results which were published on the Stock Exchange News Service on Wednesday, 26 August 2015. The electronic version of the annual financial statements can be accessed on the company?s website, www.adcock.com.



Notice of the annual general meeting

Notice is hereby given that the annual general meeting of Adcock Ingram shareholders will be held at the company?s premises, 1 New Road, Midrand, Gauteng on Thursday, 19 November 2015 at 09h00 to transact the business as indicated in the annual general meeting notice forming part of the annual financial statements.



Salient dates

*Record date to determine which shareholders are entitled to receive the notice of annual general meeting -- Friday, 16 October 2015

*Last day to trade in order to be eligible to attend and vote at the annual general meeting -- Friday, 6 November 2015

*Record date to determine which shareholders are entitled to participate and vote at the annual general meeting -- Friday, 13 November 2015

*Forms of proxy for the annual general meeting to be lodged with the company?s transfer secretaries, Computershare Investor Services (Pty) Ltd. by no later than 09h00* -- Tuesday, 17 November 2015

*any proxies not lodged by this time must be handed to the chairperson of the annual general meeting immediately prior to the annual general meeting.
26-Aug-2015
(C)
Revenue for the year jumped to R5.559 billion (2014: R3.641 billion). Gross profit soared to R2.082 billion (2014: R1.140 billion), operating profit turned around to R344.7 million (2014: loss of R974.7 million), while profit attributable to owners of the parent came in at R197.9 million (2014: loss of R965.3 million). Furthermore, headline earnings per ordinary share was 160.1 cents per share (2014: loss of 179.5 cents per share).



Dividend

The Board has declared a final gross dividend out of income reserves of 81 cents per share in respect of the year ended 30 June 2015.



Prospects

There is no useful purpose in the Board reflecting on the various past corporate actions and events that have unfavourably impacted on the Company's more recent annual commercialism and market rating, save to submit, that as a result of these past circumstances, a refocused senior management team, together with the recently structured divisional management, fully understand what needs to be done to restore the Group to its former status in the industry. They have already diligently demonstrated their commitment to that objective and have practically put the Group on a profit path which will hopefully continue as efficiencies and markets improve.



Considering the economic conditions and uncertainties in South Africa at this time and elsewhere, the currency erosion, an erratic electricity supply and an unpredictable market, the Board are satisfied with the direction and progress achieved during the past year. The Board remains optimistic on the Group's medium term prospects, which view is tempered by the recent material devaluation of the Rand.
25-Aug-2015
(Official Notice)
Adcock will announce its results for the year ended 30 June 2015 on 26 August 2015, on SENS. Shareholders are advised that a conference call will be hosted by Mr Kevin Wakeford, CEO and Mr Andy Hall, Deputy CE and FD following the results announcement. Interested parties are invited to dial in by 14:00 (South African Standard Time ((SAST)) - GMT +02:00) using the appropriate number from the list given below. You will be required to register before entering the call. A short question and answer session will follow the oral presentation.



Live Call Access Numbers For Participants

Country: Access Number

*Other Countries - International: +27 11 535 3600

*Other Countries - International: +27 10 201 6800

*South Africa - Cape Town: 021 819 0900

*South Africa - Durban: 031 812 7600

*South Africa - Johannesburg Telkom: 011 535 3600

*South Africa - Johannesburg Neotel: 010 201 6800

*South Africa - Toll-Free: 0 800 200 648

*UK - Toll-Free: 0808 162 4061



Playback Access Numbers - Playback Code: 36561

Country: Access Number

*Other Countries - International: +27 11 305 2030

*South Africa: 011 305 2030

*UK - Toll Free: 0 808 234 6771
18-Aug-2015
(Official Notice)
In the trading statement published on SENS on 5 June 2015, shareholders were advised that the Company expected to report an improvement in basic and headline earnings of at least 20% for the annual reporting period then ending on 30 June 2015, compared to the basic and headline results, statutorily reported, for the nine months ended 30 June 2014.



At the date of the aforesaid Trading Statement, the Company did not have reasonable certainty on the Group?s earnings, to enable the Company to provide more specific guidance on the range of basic earnings and/or headline earnings per share. The Board of directors of Adcock can now reveal with absolute certainty, that profits for the year ended 30 June 2015 will result in a positive basic and headline earnings per share, reversing the basic and headline losses per share incurred during the reviewed twelve-month period ended 30 June 2014.



The table below shows the reviewed basic and headline losses per share for the twelve-month period ended 30 June 2014, and the range of basic and headline earnings per share expected for the current period.

Year ended 30 June 2015 (Expected):

*Basic earnings/(loss) per share: 113.0c - 118.0c

*Headline earnings/(loss) per share: 156.0c - 161.0c



The last published actual results for the nine-months ended 30 June 2014, reflected basic and headline losses per share of 572.3 cents and 179.5 cents respectively. The financial information on which this Trading Statement is based has not been reviewed or reported on by the Company's external auditors. The results for the year ending 30 June 2015 will be released on the SENS on or about 26 August 2015.
24-Jul-2015
(Official Notice)
Adcock ordinary shareholders ("Shareholders") are referred to the announcements made by the Adcock board of directors released on the Stock Exchange News Service of the JSE Ltd. ("JSE") on 13 May 2015, 28 May 2015 and 10 July 2015, together with the posting of the Adcock Scheme document issued on 28 May 2015 ("Scheme Circular") and the AdBEE Placing document, setting out certain salient details regarding the termination of the Existing Adcock BEE Scheme, and the New Adcock BEE Scheme which includes a proposed Scheme of arrangement in terms of section 114 of the Companies Act, 71 of 2008, between Adcock and its Shareholders (the "Scheme"), and the financial effects thereof.



Further to the table of entitlements set out in Annexure I of the Scheme Circular, the final details of the Scheme election is provided below:

*Adcock shares in issue: 171 456 185

*Number of shares tendered in the Scheme: 25 842 960

*% of shares tendered in the Scheme: 15.07%

*Number of Adcock call options available: 8 000 000

*Number of Adcock call options received per share tendered: 0.30956

*Number of AdBEE shares received: 25 842 960



If a Scheme participant is required to dispose of a fraction of a Scheme share or becomes entitled to receive a fraction of an Adcock call option then such fraction shall be rounded up to the nearest Scheme share or Adcock call option if half or more; and rounded down, if the fraction is less than half of a Scheme share or Adcock call option.



If a Scheme participant holds 3 Adcock shares or less, such participant will not tender any Scheme shares due to the rounding to zero but will retain their Adcock shares and will accordingly, not receive an Adcock call option. If a Scheme participant has greater than 3 but less than 10 Adcock shares, such participant will qualify for 1 AdBEE security but will not receive any Adcock call options due to the rounding to zero.



The remaining salient dates are as follows:

*Settlement of the Scheme consideration to occur to certificated Scheme participants on Monday, 27 July

*Dematerialised Scheme participants to have their accounts with their broker or CSDP credited with the Scheme consideration on Monday, 27 July

*Scheme implementation date on Monday, 27 July
10-Jul-2015
(Official Notice)
05-Jun-2015
(Official Notice)
28-May-2015
(Official Notice)
13-May-2015
(Official Notice)
20-Apr-2015
(Official Notice)
12-Mar-2015
(Official Notice)
25-Feb-2015
(Official Notice)
Shareholders of Adcock were advised that the Company has concluded its mandate with Deutsche Securities (SA) (Pty) Ltd. and is in the process of appointing Rand Merchant Bank, a division of FirstRand Bank Ltd., to act as JSE sponsor to Adcock. It is envisaged that such an appointment will be effective from 1 March 2015.
23-Feb-2015
(Official Notice)
23-Feb-2015
(C)
Adcock changed its financial year end to 30 June. This will be the first interim results for 31 December.



Results compared to 6 months ended 31 December 2013.



Revenue increased to R2.72 billion (R2.69 billion). Gross profit rose to R993.0 million (R968.3 million) and operating profit went up to R200.3 million (R144.5 million). Profit attributable to owners of the parent increased to R141.9 million (R102.4 million). In addition, headline earnings per share shot up to 83.8c (earnings of 60.7c).



Dividend

The Board has resolved that notwithstanding the relevant improvement in the Group results, no interim dividend in respect of the period ended 31 December 2014 will be declared.



Prospects

The reorganisation and general restructure of the business, including the implementation of a series of corrective measures and actions, has resulted in a more energised workplace instilling greater pride and confidence in staff and management within all of the Group's operating divisions. Notwithstanding the volatile economics and uncertainties in both South African and world markets, the Board is satisfied with the direction and progress made during this reporting period.
18-Feb-2015
(Official Notice)
Shareholders of the Company are referred to the announcements published on the Stock Exchange News Service of the JSE (SENS) on 20 and 27 May 2014, wherein shareholders were advised that the financial year end of the Company was changed from 30 September to 30 June. The table below includes the published basic and headline loss per share for the interim period 1 October 2013 to 31 March 2014. In addition, for comparative purposes, financial information for the previously unpublished interim results for the period 1 July 2013 to 31 December 2013, which are the sole responsibility of the directors of the Company, are also disclosed on the same basis as any other interim period, being an extract of management accounts.



Interim 1 July 2014 - 31 December 2014: expected range

*Basic (loss)/earnings per share: 82.0c -85.0c

*Headline (loss)/earnings per share: 81.0c - 84.0c



To understand the expected change between the respective periods, shareholders are referred to the trading statement released on SENS on 31 January 2014 as well as the unaudited financial results for the six-month period ended 31 March 2014 released on SENS on 27 May 2014. The commentary on those financial results contained an explanation for the loss generated for the period 1 October 2013 to 31 March 2014, which included poor trading conditions, margin pressures, currency depreciation and cost input inflation, compounded by increased overheads including R91 million related to corporate activity. The period 1 July 2013 to 31 December 2013 contained costs of R47 million relating to corporate activity which costs do not recur in the current period. The financial information on which this trading statement is based has not been reviewed or reported on by the Company's external auditors. The Company's interim financial results for the six-month period ended 31 December 2014, including the comparative period for 31 December 2013, are expected to be released on SENS on or about 23 February 2015.
24-Nov-2014
(Official Notice)
Adcock shareholders are advised that at the annual general meeting of Adcock shareholders ("Annual General Meeting") held on Friday, 21 November 2014 (in terms of the notice of the Annual General Meeting distributed to Adcock Ingram shareholders on Thursday, 23 October 2014), all of the resolutions tabled were passed by the requisite majority of votes.
24-Nov-2014
(Official Notice)
In accordance with paragraph 3.59 of the Listings Requirements of the JSE Ltd., shareholders are advised that following the establishment of the Acquisitions Committee by the board of directors of Adcock, in accordance with the Company's memorandum of incorporation and the Board Charter, the following directors will serve as its members with immediate effect:



Messrs Brian Joffe; Clifford Raphiri; Roshan Morar; Lindsay Ralphs; and Michael Sacks.



Messrs Andrew Hall and Kevin Wakeford will serve on the Acquisitions Committee as permanent invitees.

21-Nov-2014
(Official Notice)
Shareholders are informed that the Chairman of the Board of Directors of Adcock advised shareholders present at the annual general meeting that the company made approximately R50m profit after tax in the three month period ended 30 September 2014.



Shareholders are further advised that the company is reviewing the structure of the BBBEE transaction that was concluded in 2010.
23-Oct-2014
(Official Notice)
Shareholders are advised that Adcock's 2014 integrated report, containing the annual financial statements for the nine-month period ended 30 June 2014 and the notice convening the annual general meeting, has been distributed to shareholders on Thursday, 23 October 2014. In terms of section 59(1) of the Companies Act 71 of 2008, as amended,("Companies Act") the board of directors of Adcock (the "board") has set the record date to determine which shareholders are entitled to receive the notice of the company's annual general meeting as Friday, 17 October 2014. As a result of the current South African Post Office strike which may adversely affect postal deliveries, shareholders are further advised that they can also access the integrated report, on the company's website www.adcock.com from Friday, 24 October 2014, or alternatively obtain a copy of the integrated report from the company's registered office.



Adcock's annual financial statements for the nine- month period ended 30 June 2014 contain no modifications to the abridged audited results which were released on the Stock Exchange News Service of the JSE Ltd. on Thursday, 28 August 2014. The company's auditors, Ernst - Young Inc, have audited the annual financial statements and their unqualified report is available for inspection at the company's registered office.



Notice is hereby given that the annual general meeting of the company will be held on Friday, 21 November 2014 at 09:00 at the company's premises at 1 New Road, Midrand, Gauteng, to transact the business as stated in the notice of the annual general meeting. In terms of section 59(1) of the Companies Act, the board has set the record date to determine which shareholders are entitled to participate in and vote at the annual general meeting as Friday, 14 November 2014. The last day to trade to be able to participate in and vote at the annual general meeting is Friday, 7 November 2014.
28-Aug-2014
(Official Notice)
In accordance with paragraph 3.59 of the Listings Requirements of the JSE Ltd. ("JSE"), shareholders are advised that with effect from 27 August 2014 the Chairman of the board of directors of Adcock Ingram ("the Board"), Mr Brian Joffe, will chair the HR, Remunerations and Nominations Committee, when constituted as the Nominations Committee.



In instances where the Chairman of the Board is conflicted, the Lead Independent Director of the Board, Mr Clifford Raphiri, will chair the Nominations Committee which is in compliance with paragraph 3.84(a) of the Listings Requirements of the JSE. When constituted as the Nominations Committee, the Committee will have the following membership: Messrs Brian Joffe; Michael Sacks and Clifford Raphiri.
28-Aug-2014
(C)
Results are for the nine month period ended 30 June 2014. Shareholders are reminded of the change in year-end from September to June.

Turnover for the period ended 30 June 2014 came in at R3.6 billion. Gross profit for the period was R1.1 billion, operating loss came in at R974.7 million and loss attributable to owners of the parent was R965.3 million. Furthermore, headline loss per ordinary share came in at 179.5cps.



Dividend

No dividend was declared for the period.



Prospects

Going forward, the reorganisation and corrective actions within the operating divisions are expected to stabilise the Group's immediate state of affairs, but it is too early to provide shareholders with any comfort regarding a return to profitability in the short term. However, in the short period since this curative initiative and renewed focus has occurred, a new culture of productivity and accountability has already taken root, hopefully restoring a positive direction in each of the business units and an improved demand for the Group's product range.



Notwithstanding the unfortunate events and results recorded for the period under review, the Group owns, produces and distributes an impressive range of pharmaceutical and medical products and given the Group's world-class production facilities, the Board remains optimistic about the longer term prospects
18-Aug-2014
(Official Notice)
Further to the Stock Exchange News Service ("SENS") announcement on 5 August 2014, and in terms of paragraph 3.4(b) of the JSE Listings Requirements, shareholders of Adcock Ingram are provided with further guidance in regard to the financial results for the nine-month period ended 30 June 2014. The board of Directors of Adcock Ingram (the "board") can now confirm with a reasonable degree of certainty that the financial results for the aforesaid period will be reported substantially as follows:



Loss Range Per Share 30 June 2014 Cents and Percentage Range Change

*Basic -- (570.0 cents) - (580.0 cents); (311%) - (315%)

*Headline -- (175.0 cents) - (185.0 cents); (164%) - (168%)



The group recorded an extremely weak trading performance for the nine-month period ended 30 June 2014, not only as a result of a general decline in turnover, but also through significant pressures on margins and profits arising, inter alia, through unfavourable currency conversion rates, key overhead inflation, and an inadequate single exit price percentage escalation. In addition, certain of the group's manufacturing facilities operated at relatively low levels of production capacity, intensifying the adverse consequences of under recovered fixed costs.



Having regard to the substantive reorganization and structural changes within the business, several substantial impairments were found to be necessary in this period and the financial impact has been included and accounted for in the guidance statistics set out above.



It is too early for the board to provide shareholders with any comfort regarding a return to profitability in the short term, but the board remains optimistic about the group's longer term prospects.



The company's audited financial results for the nine-month period ended 30 June 2014 will be released on SENS on or about 28 August 2014.
05-Aug-2014
(Official Notice)
Shareholders of Adcock Ingram (Shareholders) are referred to the announcements published on the Stock Exchange News Service (SENS) on 20 and 27 May 2014, wherein Shareholders were advised that the financial year end of the Company was changed from 30 September to 30 June and that substantive structural and other changes were being effected within the business. Pursuant thereto, a final assessment on the extent of the financial impact of providing for these corrective actions remains work in progress.



The board of directors of Adcock Ingram (Board) has concluded with absolute certainty that the financial results for the nine-month period ended 30 June 2014 will result in a basic and headline loss per share, indicating a significant reversal in the Company?s operating performance compared to the corresponding nine-month period ended 30 June 2013 and the year ended 30 September 2013. Furthermore, the effects of the corrective action referred to above are unlikely to yield significant improvement in the short term. The Board however remains optimistic about the Company?s long term prospects.



The Board is mindful of the disappointment with which this Trading Statement is likely to be received, but it is important that the information be released to Shareholders as soon as it became known. A detailed Trading Statement will be published on SENS in due course. The financial information on which this Trading Statement is based has not been reviewed or reported on by the Company's external auditors. The Company's Audited Financial Results for the nine-month period ended 30 June 2014 are expected to be released on SENS on or about 28 August 2014.
27-May-2014
(Official Notice)
Shareholders were advised that management of Adcock will be hosting a presentation to analysts on the Adcock financial results for the six months ended 31 March 2014 on 27 May 2014. The presentation will be available on the company's website at www.adcock.com from 08:30am on 27 May 2014.
27-May-2014
(C)
Revenue increased to R2.43 billion (R2.36 billion). Gross profit declined to R845.9 million (R982.7 million) and operating profit slumped to R1.9 million (R425.4 million). A net attributable loss of R41.9 million (profit of R317.2 million). In addition, a headline loss per share of 23cps (earnings of 188.1cps).



Outlook

Adcock Ingram, operating primarily in the South African market, remains concerned that the DOH approved SEP increase of 5.8% is insufficient to offset the impact of the weak Rand on active ingredient prices, and local wage and utilities inflation. Sales recovery and margin pressure therefore remains of concern in the short term.



The company is currently implementing substantive changes to its internal structures and processes in order to create more defined but decentralised business units. The changes will inter alia create autonomous operating divisions with separate focused strategies to best manage the challenges and opportunities in each of the Adcock Ingram businesses, while at the same time, facilitating full accountability in each case.



These changes, in the process of implementation, are expected to be completed by 1 July 2014, hopefully triggering a renewed focus of the group's business operations, so as to restore the company's profitability at the earliest possible time. The full financial outcome of these systems and structural changes is yet to be finalised and the impact could result in further consequential expenditure and impairments which will affect the group's audited results for the period ending 30 June 2014. While the road ahead is likely to be challenging, the board remains optimistic that management will respond to the task of successfully building on the proud history of the company over the short to medium term.
20-May-2014
(Permanent)
The company's financial year end has been changed from September to June.
20-May-2014
(Official Notice)
Shareholders are referred to the Trading Statements issued by the Company on SENS on 31 January 2014 and 19 March 2014. Pursuant thereto, shareholders are advised that the Company is expecting to report a loss per share for the interim financial period ended 31 March 2014 of between 24 cents and 25 cents, compared to earnings per share of 188.0 cents reported for the previous comparable six-month period. The headline loss per share for the subject interim financial period is expected to be between 22 cents and 24 cents compared to headline earnings per share of 188.1 cents for the previous comparable six-month period. The figures with respect to the period ended 31 March 2014 include the final write-off of all expenses related to the CFR Pharmaceuticals corporate action. The Company's interim financial results for the six-month period ended 31 March 2014 will be released on SENS on or about 27 May 2014.



Change in financial year end

The recently reconstituted Board of Directors has approved substantive changes to the Group's internal processes and structures. Management is working on the evaluation and design of these changes which are expected to be fully implemented with effect from 1 July 2014, whereafter any benefits related thereto will begin to be realised. Pursuant to the changes, shareholders are advised that for better performance management and other goal directed operational practicalities, the Company's financial year end has been changed from September to June. Accordingly the next formal results communication will be the audited financial results for the nine months ending 30 June 2014.
11-Apr-2014
(Official Notice)
Shareholders are advised that following the appointments of Dr Anna Mokgokong; Messrs Roshan Morar and Lindsay Ralphs to the board of directors of the Company, that with effect from 10 April 2014 the vacancies to the Board Committees have been filled as follows:

* Messrs R Morar, L Ralphs and M Sacks have been appointed as members of the HR, Remuneration - Nominations Committee;

* Dr A Mokgokong and Mr K Wakeford have been appointed as members of the Social, Ethics - Transformation Committee;

* Mr R Morar has been appointed as a member of the Audit Committee; and

* Mr M Sacks has been appointed as a member of the Risk and Sustainability Committee.
10-Apr-2014
(Official Notice)
Shareholders are advised that, at the extraordinary general meeting of Adcock held at 10:00 on Thursday, 10 April 2014, the ordinary resolutions relating to the election of Mr LP Ralphs, Dr A Mokgokong and Mr R Morar as non-executive directors of the company, as set out in the notice convening the extraordinary general meeting dated 7 March 2014, were passed by the requisite majority of the voting rights exercised on these resolutions.
03-Apr-2014
(Official Notice)
Mr Kevin Wakeford has been appointed as the chief executive officer of Adcock with immediate effect.
01-Apr-2014
(Official Notice)
Shareholders are notified that Dr Jonathan James Louw has tendered his resignation as the Company's Chief Executive Officer with immediate effect to pursue other interests. The board of directors of Adcock will make a further announcement regarding the Chief Executive Officer position in due course.
19-Mar-2014
(Official Notice)
Shareholders are advised that, at the extraordinary general meeting of Adcock held at 11:00 on Wednesday, 19 March 2014, the special resolutions relating to the remuneration payable to non-executive directors for their services as directors for the period 1 February 2013 to 31 January 2014 and for the period from 1 February 2014, as set out in the notice convening the extraordinary general meeting dated 13 February 2014, were passed by the requisite majority of the voting rights exercised on these resolutions.
19-Mar-2014
(Official Notice)
07-Mar-2014
(Official Notice)
Adcock Ingram shareholders are advised that a circular relating to the election of Mr Lindsay Peter Ralphs, Dr Anna Mokgokong and Mr Roshan Morar as directors of the Company, was distributed to Adcock Ingram shareholders today, Friday, 7 March 2014 (the Circular). The Circular incorporates a notice of general meeting of Adcock Ingram shareholders to consider and, if deemed fit, approve, with or without modification, the ordinary resolutions contained in the notice convening such meeting (the Extraordinary General Meeting). The Extraordinary General Meeting of Voting Members (as defined in the Circular) will, subject to any adjournment, cancellation or postponement of the meeting by Adcock Ingram, be held in the auditorium at Adcock Ingram?s office, 1 New Road, Midrand, Gauteng, South Africa commencing at 10h00 on Thursday, 10 April 2014.



Salient Dates and Times

*Record date to determine which Adcock Ingram Shareholders are entitled to receive the Circular Friday, 28 February 2014

*Circular issued to Adcock Ingram Shareholders and notice convening the Extraordinary General Meeting released on SENS on Friday, 7 March 2014

*Notice convening the Extraordinary General Meeting published in the South African press on Monday, 10 March 2014

*Last day to trade Adcock Ingram Shares on the JSE in order to be recorded in the Register on the Voting Record Date in order to be eligible to vote at the Extraordinary General Meeting (see note 1 below) on Friday, 28 March 2014

*Voting Record Date on which Adcock Ingram Shareholders must be recorded in the Register in order to vote at the

*Extraordinary General Meeting (see note 2 below) on Friday, 4 April 2014

*Last date and time to lodge forms of proxy for the Extraordinary General Meeting with the Transfer Secretaries by 10h00 (see note 3 below) on Tuesday, 8 April 2014

*Extraordinary General Meeting to be held at 10h00 on Thursday, 10 April 2014

*Results of Extraordinary General Meeting released on SENS on Thursday, 10 April 2014

*Results of Extraordinary General Meeting published in the South African press on Friday, 11 April 2014
26-Feb-2014
(Official Notice)
Adcock shareholders are advised of the following appointments to the board of directors of the company ("the board") with effect from 25 February 2014.



Mr Brian Joffe has been appointed as non-executive Chairman of the board of directors of the company and Mr Michael (Motty) Sacks has been appointed as an independent non-executive director and Chairman of the Audit Committee. In addition, Mr Clifford Raphiri, currently an independent non- executive director of Adcock, has been appointed as the lead independent director, as required by the JSE Ltd. Listings Requirements, and in accordance with the King Code, in situations where the Chairman of the board is not independent.



In terms of the Companies Act, 71 of 2008, and the company's MOI at least 50% of the directors must be elected by the shareholders of the company. Consequently, an Extraordinary General Meeting of the company will be convened as soon as possible to elect Dr Anna Mokgokong, Mr Roshan Morar and Mr Lindsay Ralphs as directors of the company.



Until such time as the abovementioned Extraordinary General Meeting has been held and these persons are elected as directors, they will be invited by the board to attend the meetings of directors.
19-Feb-2014
(Official Notice)
13-Feb-2014
(Official Notice)
13-Feb-2014
(Official Notice)
Adcock shareholders are referred to the joint announcement released on the Stock Exchange News Service of the JSE Limited by Adcock and CFR ("the Parties") on Friday, 7 February 2014, advising that the Parties had entered into a Termination Agreement providing for the consensual termination of the Transaction Implementation Agreement concluded between the Parties on 11 September 2013, as amended ("TIA")and the termination of the scheme of arrangement proposed between Adcock and the holders of Adcock ordinary shares (other than the holder of treasury shares) in relation to the CFR offer ("Scheme").



In terms of the Termination Agreement, the termination of the TIA and the Scheme was conditional upon receipt of written exemption from the TRP from, among other things, the application of regulation 101 (2) of the Companies Regulations, 2011.



Adcock shareholders are advised that CFR has now received the requisite exemption from the TRP and, accordingly, the Termination Agreement is now effective.
07-Feb-2014
(Official Notice)
Given that all relevant information regarding the intended consensual termination of the transaction implementation agreement between Adcock and CFR, is now in the public domain, shareholders are advised that they are no longer required to exercise caution when dealing in the company's securities.
07-Feb-2014
(Official Notice)
Adcock shareholders are referred to the announcements released on the Stock Exchange News Service ("SENS") of the JSE Ltd. by the company and by The Bidvest Group Ltd. ("Bidvest") on Friday, 31 January 2014, regarding the acquisition by a consortium comprising Bidvest and Community Investment Holdings Proprietary Ltd. of approximately 34.5% of the issued share capital of the company (excluding the A and B ordinary shares and the treasury shares) ("Adcock Ordinary Shares").



Shareholders are advised that Adcock and CFR:

1. have consulted and are of the common view that there is no prospect that the special resolutions to approve the scheme of arrangement proposed between the company and the holders of Adcock Ingram Ordinary Shares in relation to the offer from CFR ("the Scheme") will be approved by the necessary 75% majority.

2. have entered into a written agreement ("Termination Agreement") providing, inter alia, -

*for the consensual termination of the TIA concluded on 11 September 2013, as amended, and accordingly for the termination of the Scheme, which termination is subject to, and will take effect upon, receipt of written exemption by the Takeover Regulation Panel ("TRP") from the requirement in regulation 101(2) of the Companies Regulations, 2011 that CFR must proceed with the transactions contemplated in the TIA. The TRP has already been approached in this regard;

*that until the exemption from the TRP is obtained, neither of the Parties shall, subject to certain exceptions, seek to enforce any provisions of the TIA, the Scheme or certain related agreements; and

*that, upon receipt of the exemption from the TRP, neither of the Parties shall have any claim against the other arising out of or in connection with the TIA or its termination.



In the circumstances, Adcock shareholders are advised the company does not intend to reconvene the Combined General Meeting and the Ordinary General Meeting to consider the resolutions to approve the Scheme, each of which was adjourned in December 2013.
04-Feb-2014
(Official Notice)
Shareholders are advised that Mr LE Sch?nknecht retired as a non-executive at the annual general meeting of Adcock held at 14:00 on Friday, 31 January 2014. Shareholders are referred to the results of the annual general meeting of Adcock announcement released on SENS on Friday, 31 January 2014 regarding the failure of the resolution in connection with the re-election of Mr AM Thompson.
31-Jan-2014
(Official Notice)
Shareholders are advised that, at the annual general meeting of Adcock Ingram held at 14:00 on Friday, 31 January 2014 (Annual General Meeting), all the ordinary resolutions set out in the Notice of Shareholders dated 18 December 2013 were passed by the requisite majority, other than the following resolutions:-

*Ordinary resolution number 1.2: The re-election of Mr AM Thompson as a director - this resolution failed.

*Ordinary resolution number 2.3: The election of Mr AM Thompson as a member of the Adcock Ingram Audit Committee (Audit Committee) this resolution failed. In terms of section 94(2) of the Companies Act 71 of 2008 (Companies Act), an audit committee comprising at least three members must be elected at the Company's Annual General Meeting. Shareholders are advised that due to the failure of ordinary resolutions 1.2 and 2.3, only 2 persons have been elected at the Annual General Meeting as opposed to the statutory requirement of 3. The board of the Company will in light of this take such steps as may be open to it to mitigate the impact of this shareholder vote on the Audit Committee?s functioning.

*Ordinary resolution number 5: Non-binding advisory vote regarding the Company?s remuneration policy this resolution failed. Although this resolution is of an advisory nature only, the Board will take the failure of this resolution into account when reviewing the Company?s remuneration policy.

31-Jan-2014
(Official Notice)
As at 31 December 2013, the end of the first quarter of trading for the 2014 financial year, group revenue was 4% ahead of the previous corresponding period, including the Cosme and Datlabs businesses which were not in the comparative period. Revenue in the Southern African business is 4% behind the corresponding period, including a sharp slow-down in the OTC and Prescription Generics portfolios. The gross profit as a percentage of sales is under extreme pressure as a result of the unfavourable revenue mix, Rand depreciation which has negatively affected the cost of imported active ingredients and other materials, and cost input inflation. Operating expenditure has been impacted by increased marketing and distribution costs, salary and wage increases across the business, and costs related to the current corporate activity.



Accordingly, shareholders are advised that Adcock Ingram's basic earnings per share ("EPS") for the six- month period ending 31 March 2014 from continuing operations are expected to be lower than the previous corresponding period's figure of 188.0 cents. Headline earnings per share ("HEPS") for the six- month period ending 31 March 2014 from continuing operations are expected to be lower than the previous corresponding period`s figure of 188.1 cents. The board is unable to provide a range as contemplated in paragraph 3.4(b) of the JSE Limited Listings Requirements at this stage of the financial period in question but has reasonable certainty that the EPS and HEPS will be lower than the previous corresponding figures by a minimum of 20%.



The financial information on which this trading statement is based has not been reviewed and reported on by Adcock Ingram?s auditors. The Company?s financial results for the six months period ending 31 March 2014 will be released on the Stock Exchange News Service of the JSE on or about 27 May 2014.

31-Jan-2014
(Official Notice)
17-Jan-2014
(Official Notice)
16-Jan-2014
(Official Notice)
Shareholders were referred to the announcement by Bidvest dated 2 December 2013 in which a consortium comprising The Bidvest Group Ltd. ("Bidvest") and CIH ("the Consortium") made a cash offer to acquire up to 34.5% of the issued ordinary shares of Adcock (excluding treasury shares) for a cash consideration of R70.00 per Adcock ordinary share ("the Offer").



Since Bidvest's initial approach in March 2013 to the Board of Directors of Adcock, Adcock has been subjected to a protracted period of continuous delays throughout which time the attention of the Adcock Board and management has been diverted from optimising the operational performance of Adcock. This has been exacerbated by the protracted process relating to the offer by CFR Pharmaceuticals SA ("CFR Offer"), including the adjournment of the scheme meeting and the delay in issuing the documentation relating to the new CFR Offer. This will further extend the process.



The Consortium believes it is in its best interests to be in a position to deal in Adcock shares with complete flexibility. Accordingly Adcock shareholders are hereby advised that the Offer will close at the close of business 17:00 on Tuesday, 4 February 2014.
09-Jan-2014
(Official Notice)
Adcock shareholders are referred to the announcements released on the SENS on Friday, 13 December 2013 and Wednesday, 18 December 2013 and published in the South African press on Tuesday, 17 December 2013 and Thursday, 19 December 2013, respectively, which referred to, inter alia, the intention by CFR Pharmaceuticals S.A. ("CFR") to increase the total consideration payable to the holders of Adcock ordinary shares in terms of the scheme of arrangement proposed between Adcock and Adcock ordinary shareholders (other than the ordinary shares held by Adcock's wholly owned subsidiary) ("the Revised Offer") ("the Scheme") and the adjournment of the Combined General Meeting and the Ordinary General Meeting ("the General Meetings") convened on Wednesday, 18 December 2013.



The adjournment of general meetings

Due to regulatory approval of the relevant shareholder documentation taking longer than anticipated in December 2013, the adjourned General Meetings are now likely to resume in mid-February 2014. Shareholders will be notified of the revised salient dates and times in a further announcement.



Pro forma financial effects

The table below sets out the pro forma financial effects of the Scheme on Adcock Ordinary Shareholders, for which the directors of Adcock are responsible, based on the results of Adcock for the year ended 30 September 2013 and the assumptions set out below the table. Before - after the scheme:

* EPS: 3.49 - 0.041

* DEPS: 3.48 - 0.041

* HEPS: 3.51 - 0.041

* DHEPS: 3.50 - 0.041

* NAVPS: 22.32 - 1.19

* NTAVPS: 13.81 - (0.44)

* Weighted average number of shares in issue ('000): 168 618 - 11 134 957

* Shares in issue at period-end ('000): 168 328 - 11 134 957

* Diluted number of shares ('000): 168 753 - 11 213 625



Renewal of cautionary

Further to the cautionary announcement and renewals thereof dated 2 December 2013, 3 December 2013, 4 December 2013, 13 December 2013 and 18 December 2013, respectively, released by the Company, shareholders are advised to continue exercising caution when dealing in the Company's securities until a further announcement is made.
18-Dec-2013
(Official Notice)
Adcock Ingram and CFR are still in the process of revising the pro forma financial effects of the revised terms of the Scheme on Adcock Ingram shareholders. Adcock Ingram shareholders are advised to continue exercising caution when dealing in the Company's securities until a further announcement is made.

18-Dec-2013
(Official Notice)
Adcock Ingram shareholders are referred to the announcement released on the SENS of the JSE on Friday, 13 December 2013 and published in the press on Tuesday, 17 December 2013 (the 13 December announcement). The 13 December announcement referred to, inter alia, a notice received from CFR Pharmaceuticals S.A. (CFR) to increase the total consideration payable to the holders of Adcock Ingram ordinary shares in terms of the scheme of arrangement proposed between Adcock Ingram and Adcock Ingram ordinary shareholders (other than the ordinary shares held by Adcock Ingram?s wholly-owned subsidiary) (the Scheme), and a consequent recommendation by the Adcock Ingram Independent Board to adjourn the Combined General Meeting and the Ordinary General Meeting (General Meetings) scheduled to take place on Wednesday, 18 December 2013 to consider the proposed resolutions in respect of the Scheme. Adcock Ingram shareholders are advised that the General Meetings were convened in terms of the notices of the respective General Meetings dated 18 November 2013 on Wednesday, 18 December 2013 at 10:00am and 12:00 noon South Africa time respectively.



At each of the General Meetings resolutions to adjourn the General Meetings were proposed, and approved by the requisite majorities. The General Meetings have accordingly been duly adjourned until a date still to be announced, but anticipated to be around the end of January 2014. A form of proxy lodged or a letter of representation issued for one or both of the General Meetings will remain valid for the relevant adjourned General Meetings. In addition, properly completed new or replacement forms of proxy may be lodged with or posted to Computershare Investor Services Proprietary Limited, the transfer secretaries of Adcock Ingram up to at least 48 hours prior to the resumption of the adjourned General Meetings, or may be handed to the Chairman of the adjourned General Meetings not later than 10 minutes before the time of the relevant adjourned General Meeting.



18-Dec-2013
(Official Notice)
Shareholders are advised that Adcock Ingram's 2013 integrated report, containing the annual financial statements for the year ended 30 September 2013, has been distributed to shareholders on 18 December 2013 and contains no modifications to the abridged audited results which were released on the Securities Exchange News Service of the JSE Limited on 27 November 2013. The Company's auditors, Ernst - Young Inc, have audited the annual financial statements and their unqualified report is available for inspection at the Company?s registered office. Adcock Ingram?s integrated report will be available on its website www.adcock.com from 18 December December 2013.



Notice is hereby given that the annual general meeting of the Company will be held on Friday, 31 January 2014 at 14:00 at the Company's premises at 1 New Road, Midrand, Gauteng, to transact the business as stated in the notice of the annual general meeting. In terms of section 59(1) of the Companies Act 71 of 2008, as amended, the Board of Directors of Adcock Ingram has set the record date to determine which shareholders are entitled to participate in and vote at the annual general meeting as being Friday, 24 January 2014. The last day to trade to be able to participate in and vote at the annual general meeting is Friday, 17 January 2014.
13-Dec-2013
(Official Notice)
05-Dec-2013
(Official Notice)
Shareholders are advised that Professor Matthias Haus has been appointed as a member of the Audit Committee with effect from 3 December 2013. Professor Haus also serves as a member of the Risk and Sustainability Committee.
04-Dec-2013
(Official Notice)
Shareholders are referred to the announcement released on SENS on or around 17h40 South Africa time on 3 December 2013 by The Bidvest Group Ltd. ("Bidvest") on behalf of Bidvest and Community Investment Holdings (Pty) Ltd. ("CIH") (together "the Bidvest Consortium") regarding the Bidvest Consortium's legal challenge of the "CFR / Adcock Transaction".



Shareholders are advised that the Company is in receipt of an application ("Bidvest Application") brought by BB Investment Company (Pty) Ltd., a subsidiary of Bidvest, launching legal proceedings in relation to the scheme of arrangement ("the Scheme") contemplated and set out in the Combined Circular to Adcock Ingram shareholders dated 18 November 2013, as supplemented. The Bidvest Consortium is seeking orders inter alia declaring the Scheme and related transactions void and/or that the general meetings of Adcock Ingram shareholders scheduled to take place on 18 December 2013 ("General Meetings") have not been lawfully convened, and interdicting the implementation of the Scheme and related transactions. It is noteworthy, however, that the Bidvest Consortium is not seeking to interdict the holding of, or voting at, the General Meetings.



The Bidvest Application has not been brought on an urgent basis. Bidvest has indicated that it intends to have the matter argued and decided in February 2014. The Company is in the process of reviewing and taking advice on the Bidvest Application. Shareholders are therefore advised to continue exercising caution when dealing in the Company's securities until a further announcement is made.
03-Dec-2013
(Official Notice)
02-Dec-2013
(Official Notice)
Shareholders are referred to the announcements released by The Bidvest Group Ltd. this morning regarding:

*the proposed acquisition of up to 34.5% of the issued share capital of Adcock Ingram by way of a tender offer which opened at 09h00 South Africa time this morning; and

*the contemplated institution of legal proceedings in respect of the "CFR/Adcock Ingram transactions", details of which have not been provided.



The company is currently considering its position in relation to both of these announcements and will advise shareholders in due course. Shareholders are advised to exercise caution when dealing in the company's securities until a further announcement is made.
29-Nov-2013
(Official Notice)
Further to the Combined Circular to Adcock Shareholders and the Combined Prospectus and Pre-Listing Statement of CFR Pharmaceuticals SA ("CFR"), dated 18 November 2013, and the Supplement to the Combined Circular to Adcock Ingram Shareholders dated 21 November 2013, Adcock Ingram shareholders are informed that, following a request from an Adcock Ingram shareholder, the directors of Adcock Ingram have decided to make certain additional documents available for inspection at the offices of its sponsor, Deutsche Securities (SA) (Pty) Ltd. (being 3 Exchange Square, 87 Maude Street, Sandton, 2196).



These documents (a number of which are in Spanish) comprise Promissory Notes, Powers of Attorney, Pledges, and Guarantees to which CFR and/or certain of its subsidiary companies are party, as well as a copy of certain resolutions of the directors of Adcock Ingram and redacted versions of the Escrow and Flow of Funds Agreement and the Transaction Closing and Flow of Funds Agreement.
27-Nov-2013
(Official Notice)
Shareholders are advised that management of Adcock will be hosting a presentation to analysts on 27 November 2013 on the Audited Group Annual Financial Results for the year ended 30 September 2013. The presentation is available on the Company's website at www.adcock.com.
27-Nov-2013
(C)
19-Nov-2013
(Official Notice)
The company is due to release its results for the financial year ended 30 September 2013 on Wednesday, 27 November 2013. 2013 has been a particularly challenging year for the Company. Trading margins came under pressure as a result of competitive market conditions and the impact of the weaker rand on active ingredient costs.



Notwithstanding these challenging market and cost conditions, Turnover for the financial year ended 30 September 2013 is expected to be between 18% and 19% higher compared to 2012, translating into an Earnings Before Interest, Tax, Depreciation and Amortisation ("EBITDA") increase of between 10% and 11% compared to 2012.



Headline earnings per share ("HEPS") and earnings per share ("EPS") for the financial year ended 30 September 2013 are expected to be between 17% and 18% lower compared to 2012. In 2013 the average cash position turned into a net overdraft position following the acquisition of certain assets from the Cosme Group in India and the effective tax rate normalised following the expiry of the Strategic Industrial Project Allowance in 2012.
18-Nov-2013
(Official Notice)
Adcock shareholders are referred to the announcement released on SENS on Friday, 15 November 2013 and published in the South African press on Monday, 18 November 2013 relating to a firm intention by CFR Pharmaceuticals SA ("CFR") to make an offer to acquire 100% of the issued share capital of Adcock Ingram, other than the issued "A" and "B" ordinary share capital of Adcock Ingram and any ordinary shares held by subsidiaries of the Company, by way of a scheme of arrangement ("the Scheme").



Distribution of the circular

The combined circular to Adcock Ingram shareholders containing details of the Scheme ("the Circular") incorporating notices of meetings of Adcock Shareholders to approve the Scheme, forms of proxy and an election, surrender and transfer form, and accompanied by the CFR combined prospectus and pre-listing statement, are being distributed today, 18 November 2013. Adcock shareholders are advised that the Circular and the Prospectus will also be available on Adcock's website www.adcock.com. Copies of the Circular and the Prospectus may be obtained from the registered office of Adcock Ingram and the financial adviser to Adcock Ingram, details of which are set out in the Circular. The Circular and the supplement together with a non-official translation thereof into Spanish will be filed, as required by the Chilean Securities Market Law, with the Superintendencia de Valores y Seguros ("SVS"), with a copy provided to all stock exchanges on which CFR?s shares are currently listed in Chile, and published on CFR's website http://www.cfr-corp.com.



The general meetings

The Scheme will be put to a vote at a meeting of all holders of shares in Adcock Ingram, other than the holder of Adcock Ingram?s treasury shares, (the "Combined General Meeting") and at a meeting of the holders of ordinary shares in Adcock Ingram (that is, excluding the A Ordinary Shares and the B Ordinary Shares) other than the holder of Adcock Ingram?s treasury shares, (the "Ordinary General Meeting"), (collectively "the General Meetings") to be held in the Auditorium at Adcock's offices, 1 New Road, Midrand, Gauteng, South Africa at 10h00 in respect of the Combined General Meeting and 10h30, or ten minutes after the conclusion or adjournment of the Combined General Meeting, whichever is the later, in respect of the Ordinary General Meeting, on Wednesday, 18 December 2013.
15-Nov-2013
(Official Notice)
The presentation will take place on Friday 15 November 2013 at 15h30 in the Il Paviglione room of The Michelangelo Hotel, Nelson Mandela Square, Sandton, Johannesburg. The presentation will also be webcast at http://themediaframe.eu/links/adcock131024.html.
15-Nov-2013
(Official Notice)
30-Oct-2013
(Official Notice)
11-Sep-2013
(Official Notice)
Adcock shareholders are cautioned that there is no certainty at this stage that the potential offer will be made or that the scheme will be either proposed or implemented. The potential offer may have a material effect on the price of the company's securities. Accordingly, shareholders are advised to continue exercising caution when dealing in the company's securities until a further announcement is made.
11-Sep-2013
(Official Notice)
15-Aug-2013
(Official Notice)
Shareholders are referred to the announcement dated 3 July 2013 in which the independent board of directors of Adcock ("Independent Board") notified Adcock shareholders that the Company had entered into discussions with CFR Pharmaceuticals S.A. ("CFR") regarding a non-binding offer that could lead to CFR making a cash and shares offer to acquire 100% of the issued share capital of Adcock Ingram, excluding treasury shares, by way of a scheme of arrangement ("the Potential Offer"). Shareholders are advised that discussions with CFR regarding the Potential Offer are ongoing. Whilst there is still no certainty that a firm offer will either be proposed or implemented, the Independent Board continues to engage exclusively with CFR with a view to a firm offer being made to Adcock shareholders by way of a scheme of arrangement. The full details of the Potential Offer will be communicated to Adcock shareholders and the market if and when a firm offer is made by CFR.



The Independent Board has noted recent speculation regarding the Company. Subsequent to the Company entering into exclusive discussions with CFR, the Independent Board has received further unsolicited proposals from potential offerors, each of which contemplates a scheme of arrangement and therefore the co-operation of the Independent Board. The Independent Board must evaluate any bona fide proposal submitted to the Company that could maximise value for Adcock shareholders and promote the interests of the Company. In this regard, the Independent Board confirms that it has not received any proposal that it at present regards as being more favourable than the Potential Offer.



The Independent Board is conscious of its legal and regulatory obligations not to publish misleading information nor information that may give rise to uncertainty and affect the integrity of the marketplace to the detriment of Adcock shareholders. Accordingly, the Independent Board does not intend to publish the details of every proposal it receives. The Potential Offer may have a material effect on the price of the Company's securities. Accordingly shareholders are advised to continue exercising caution when dealing in the Company's securities until a further announcement is made.
03-Jul-2013
(Official Notice)
04-Jun-2013
(Official Notice)
Shareholders were advised that management of Adcock will today be hosting a presentation to analysts on the unaudited results for the six months ended 31 March 2013. The presentation will be available on the company's website at www.adcock.com from 08:30 am on 4 June 2013.
04-Jun-2013
(C)
Revenue was up 9% to R2.5 billion (R2.3 billion). Gross profit was 1% lower at R1 billion (R1.1 billion) and operating profit was down 9% to R474.9 million (R435.4 million). Net attributable profit declined to R317.2 million (R335.3 million). In addition, headline earnings per ordinary share fell 5% to 188,1cps (198,7cps).



Dividend

A gross interim ordinary dividend of 86cps has been declared.



Outlook

The government tender business is benefiting from significantly increased volumes which are expected to drive greater efficiencies in the supply chain. The factories are gearing up to the increased demand and the business is confident of its ability to meet Government requirements on a sustainable basis.



The multinational partner of choice strategy continues to deliver attractive value with the recent additions of Lundbeck and Novo-Nordisk. Additional collaborations are being explored to continue the path of revenue stream diversification and to decrease mature product dependence. Supply chain collaborations will address the challenge in extending multinational collaboration partnerships into sub-Saharan Africa.



Whilst registration delays at the MCC continue to impede the ability of the company to bring a material number of new products to the market, further new product launches are planned for the third quarter. Recent MCC registrations include Irbesartan and a triple-combination ARV therapy.



The East Africa turnaround is on course with regulatory bottlenecks in Uganda and Tanzania having been resolved. Inspection of Adcock's factories by the Ethiopian Pharmaceutical Regulatory Authorities has commenced and bodes well for entry into that growing market. In Ghana, the new management team is progressing well with revamping the factory and distribution infrastructure.



The group continues to maintain its focus on the acquisition of businesses and brands in high growth emerging markets. The impact of the current economic climate on consumer spending is concerning. Margins will continue to be impacted by cost pressures and active ingredient prices which are directly linked to currency fluctuations, but in the second half of the financial year will be mitigated by the recent SEP increase. The second six months of the year will incorporate a determined focus on improving the working capital cycle within the business.
31-May-2013
(Official Notice)
24-May-2013
(Media Comment)
Business Day reported that private equity group Actis may be the mystery bidder for Adcock. Actis may need a partner to buy Adcock, which some analysts have valued as high as R12 billion or USD1.2 billion. If the rumours are true about Actis emerging as a possible buyer of Adcock, the private equity firm will go up against The Bidvest Group Ltd., which has bid for 60% of the company.
16-May-2013
(Official Notice)
Shareholders were advised that Mr Leon Schonknecht has been appointed as a member of the Audit Committee with immediate effect. Mr Schonknecht also serves as a member of the Risk and Sustainability Committee.
09-May-2013
(Official Notice)
Shareholders were advised that the board of directors of Adcock ("the board") is in receipt of non-binding proposals ("proposals") regarding potential transactions that would, if implemented, result in an offer being made to Adcock shareholders to acquire 100% of or a controlling interest in the company's securities.



The board has previously stated that it will consider any proposal, made in good faith, which could serve to create value for Adcock Ingram shareholders and promote the interests of the company. In this regard, the board and management continue to explore all opportunities to create value for Adcock shareholders whilst remaining focused on executing the company's strategic plans.



The board, together with its advisers, are evaluating the proposals. Shareholders were cautioned that there is no certainty at this stage that the proposals will lead to a formal transaction either being proposed or concluded.



In the interests of transparency and certainty, the board advised shareholders that no new proposal has been received from The Bidvest Group Ltd. since its original proposal, submitted to the board on 22 March 2013, which lapsed on 2 April 2013.



Shareholders were advised to exercise caution when dealing in the company?s securities until a further announcement is made.
23-Apr-2013
(Official Notice)
Shareholders are advised that on Friday, 12 April 2013 the Board of Directors of the Company, acting in accordance with section 94(6) of the Companies Act 71 of 2008, appointed Mr Andrew Thompson as the Chairman of the Audit Committee. The appointment of Mr Thompson to this position follows the resignation of Mr Eric Diack as an independent non- executive director of the Company, Chairman of the Company's Audit Committee and as member of the Company's Risk and Sustainability Committee with effect from 22 March 2013.
04-Apr-2013
(Official Notice)
02-Apr-2013
(Official Notice)
The Independent Board of Adcock has reviewed the Bidvest Letter together with its external advisers, consulted with senior counsel and the Takeover Regulation Panel and engaged with the Company's shareholders representing almost two-thirds of the total issued ordinary shares, both listed and unlisted, of Adcock. The Bidvest Letter does not constitute a firm intention by Bidvest to make an offer to Adcock shareholders as contemplated in the Companies Act. No firm intention announcement has been made and no regulated timetable has been initiated



Bidvest did not engage with the board of Adcock regarding the proposal of a scheme of arrangement prior to the submission of the Bidvest Letter In light of the Independent Board's fundamental legal and material concerns with the Bidvest Proposal, the Independent Board will not propose a scheme of arrangement based on the Bidvest Proposal The Independent Board therefore expresses no view with respect to value at this stage.



The Independent Board recognises that the timing of the Bidvest Proposal is opportunistic given the significant progress that has been made by the Company in executing its strategic plans (including completion of a R1.5 billion multi-year investment programme), the benefits of which have yet to be fully realised. No guidance has been provided by Bidvest regarding the potential benefits and areas of synergy that may arise from a Bidvest-controlled Adcock in which minority shareholders may retain a significant interest



Through the actions of Bidvest, the Bidvest Proposal has been prematurely forced into the public domain, creating expectations that a transaction may eventuate. The Independent Board is concerned about the potential for prejudice to Adcock shareholders. The Independent Board will, in the interests of Adcock shareholders, consider any initiative, from any quarter, which is made in good faith and which could serve to promote the interests of the Company and create value for Adcock shareholders The Independent Board will continue engaging Adcock shareholders regarding the Company's strategic ambitions with the overriding objective of delivering value to Adcock shareholders



Renewal of cautionary announcement

Shareholders are advised to continue to exercise caution when dealing in the Company's securities until a further announcement is made.
22-Mar-2013
(Official Notice)
The shareholders of Adcock are advised that at approximately 19h00 South Africa time on Thursday, 21 March 2013, the board of directors of Adcock ("Adcock Board") received the Bidvest Letter. The Adcock Board has constituted an independent board ("Adcock Independent Board") in order to consider the Bidvest Letter.



Shareholders are alerted to the following:

* the Adcock Ingram Independent Board has had no opportunity to review or consider the Bidvest Letter;

* no negotiation has taken place between Adcock Ingram and Bidvest regarding the proposed structure, terms and conditions set out in the Bidvest Letter;

* by publishing the content of the Bidvest Letter, the Adcock Ingram Independent Board fully reserves its rights and makes no representation, concession or recommendation regarding the nature thereof or the proposals therein and gives no undertakings in relation thereto.



Acknowledging its statutory and fiduciary obligations to the Company and its shareholders, the Adcock Independent Board will together with the company's external advisers consider its position and communicate its views to Adcock shareholders in due course.



Change to the board

Shareholders are advised that Mr Eric Diack, who is also an independent non-executive director of Bidvest, has resigned as an independent non-executive director of the Company, as well as Chairman of the Company's Audit Committee and as member of the Company's Risk and Sustainability Committee with effect from 22 March 2013.



Cautionary announcement

Shareholders are advised to exercise caution when dealing in the Company's securities until a further announcement is made.
31-Jan-2013
(Official Notice)
Shareholders were advised that, at the Annual General Meeting of Adcock held at 14:00 on Thursday, 31 January 2013, all the special and ordinary resolutions set out in the Notice of Shareholders dated 21 December 2012 were passed by the requisite majority, other than special resolution number 1 relating to the remuneration of non-executive directors which was withdrawn prior to the commencement of the meeting.



Special Resolution number 3 regarding the adoption of the new Memorandum of Incorporation in terms of the Companies Act 71 of 2008 will be filed with the Companies and Intellectual Property Commission.
18-Jan-2013
(Official Notice)
Shareholders were referred to the announcements released by Adcock on 10 July 2012 and 1 November 2012 relating to the acquisition of certain intangible assets of Cosme Farma Laboratories Ltd., a pan-Indian pharmaceutical company based in Goa, India (the "transaction"). Shareholders are advised that all conditions precedent to the transaction have been met, or where appropriate, waived by Adcock. The effective date of the transaction is on 17 January 2013. Additionally, Adcock draws shareholders' attention to the following issues, which are disclosed on a voluntary basis:

*The purchase price, as previously disclosed, of R708 million has increased by R37 million to R745 million. This increase is as a result of a 5.3% decrease in the exchange rate of the South Africa rand against the Indian rupee between 10 July 2012 and 21 December 2012, the latter date being the date of conversion of South African rands to Indian rupee;

*The stamp duty, as previously disclosed, of INR240 million or R35 million has reduced by approximately INR185 million or R26 million to INR55 million or ZAR9 million;

*An annual amortisation charge of approximately INR292 million or R45 million has been calculated for inclusion in the pro forma Statement of Comprehensive Income. This charge together with the resultant tax effects does not have a material effect on the previously disclosed pro forma financial effects relating to the transaction; and

*The above amounts are based on a ZAR/INR exchange rate of 0.1474 as at 9 July 2012 and 0.1553 as at 21 December 2012, the latter being the date of conversion of South African rands to Indian rupee.
21-Dec-2012
(Official Notice)
Shareholders are advised that Adcock's 2012 integrated report, containing the annual financial statements for the year ended 30 September 2012, has been distributed to shareholders on 21 December 2012 and contains no modifications to the abridged audited results which were released on SENS on 27 November 2012. Adcock's integrated report will be available on its website www.adcock.com from 21 December 2012.



Notice was given that the annual general meeting of the company will be held on Thursday, 31 January 2013 at 14:00 at the company's premises at 1 New Road, Midrand, Gauteng, to transact the business as stated in the notice of the annual general meeting. In terms of section 59(1) of the Companies Act 71 of 2008, as amended the Board of Directors of Adcock Ingram has set the record date to determine which shareholders are entitled to participate in and vote at the annual general meeting as being Friday, 25 January 2013. The last day to trade to be able to participate in and vote at the annual general meeting is Friday, 18 January 2013.
27-Nov-2012
(C)
Revenue for the year grew 2.4% to R4.6 billion (R4.5 billion) whilst gross profit fell 3.5% R2.1 billion (R2.2 billion). Operating profit decreased by 18.7% to R868.8 million (R1.1 billion). Net profit attributable to owners of the parent lowered to R705.6 million (R754.2 million). Furthermore, headline earnings per share narrowed by 9.2% to 422.4cps (465.1cps).



Dividend

The board has declared a final dividend of 115 cents per share for the year ended 30 September 2012 out of income reserves, bringing the dividend for the year to 201 cents per share (2011: 187 cents per share).



Prospects

The international accreditation of our recently completed manufacturing facilities remains a key focus area during the next year as the group concludes its investment in its supply chain.



Adcock maintains its focus on the acquisition of businesses and brands in high growth emerging markets in Africa and India. It expects to conclude the acquisition of Cosme Farma in January 2013. The group continues to invest in brands, people and customers off its existing platform.



The multi-national partner of choice strategy continues to deliver value with the recent addition of a co-operation agreement with Lundbeck. Additional collaborations are being explored to continue the path of revenue diversification and decrease the dependence on mature products. Supply chain collaborations will address the challenge in extending multi-national collaborations partnerships into sub-Saharan Africa.



New generic product launches are planned for early in the year in the cardiovascular category and further innovation will be taken to market on the Complementary Alternative Medicines (CAMs) portfolio.



The current economic climate remains uncertain and the impact on consumer spending is concerning. Margins will continue to be impacted by cost pressures, particularly labour, transport and utilities, and by active ingredient prices which are directly linked to currency fluctuations.
01-Nov-2012
(Official Notice)
Shareholders were referred to the announcement released by Adcock Ingram on SENS on 10 July 2012, relating to the acquisition by Adcock Ingram through its wholly owned subsidiary, Adcock Ingram Healthcare Private Ltd., of certain assets of Cosme Farma Laboratories Ltd. ("Cosme") ("the Transaction") and were advised that the regulatory approvals in India are still in process. The previously anticipated closing date for the Transaction, being 31 October 2012, has not been achieved. In terms of an extension agreement entered into between Adcock Ingram and Cosme the closing date for the Transaction has been extended to 31 January 2013.
10-Jul-2012
(Official Notice)
01-Jun-2012
(Official Notice)
Professor Mattias Haus has been appointed as a non-executive director of Adcock with effect from 1 June 2012.
29-May-2012
(Official Notice)
The management of Adcock presented the group's interim results for the six-month period ended 31 March 2012 at an investor presentation on the 29th of May 2012. This presentation is available on the Adcock website at www.adcock.com.
29-May-2012
(C)
Turnover increased by 5% to R2.3 billion (R2.2 billion). Gross profit was down 1% to R1.050 billion (R1.059 billion). Operating profit was 17% lower at R435.4 million (R526.2 million). Net attributable profit declined to R335.3 million (R353.4 million). In addition, headline earnings from continuing operations on a per share basis fell 10% to 198.7c (221.3cps).



Dividend

A gross ordinary interim dividend of 86cps has been declared.



Outlook

The upgrades to the Critical Care and Wadeville manufacturing plants have been completed and these will operate at full capacity for the second half of the year. The expansion to the Midrand distribution centre remains on course to be finished by the end of the financial year. The completion and commissioning of the high-volume liquids plant at Clayville, also scheduled for this year, will conclude the group's investment in its supply chain. Internationally-accredited manufacturing plants and direct to customer distribution capability will strengthen the group's competitiveness.



The multi-national partner of choice strategy continues to deliver value with the recent addition of co-operation agreements with Novo Nordisk and Lundbeck. Additional collaborations are being explored to continue the path of revenue stream diversification and decrease the dependence on mature products. Supply chain collaborations will address the challenge in extending multi-national collaboration partnerships into sub-Saharan Africa.



Whilst registration delays at the MCC continue to impede the ability of the group to bring new products to market, new product launches are planned for early in the third quarter in the Feminine Health and OTC segments. The group continues to search for acquisition opportunities in high growth emerging markets, particularly Africa and India. The successful registration and resourcing of its wholly-owned Indian subsidiary represents important capacity in support of this objective.



The effect of the current economic climate on consumer spending is concerning. Margins will continue to be impacted by cost pressures, particularly labour, transport and utilities, and by active ingredient prices which are directly linked to currency fluctuations.
22-Nov-2011
(Official Notice)
Shareholders are advised that management of Adcock on 22 November hosted a presentation to analysts on the Adcock group results for the year ended 30 September 2011. The presentation is available on the company's website at www.adcock.com.
22-Nov-2011
(C)
28-Oct-2011
(Official Notice)
Shareholders were advised that Adcock's basic earnings per share ("EPS") for the financial year ended 30 September 2011 from continuing operations are expected to be between 27% and 30% higher than the previous corresponding year's figure of 354.9 cents. Headline earnings per share ("HEPS") for the financial year ended 30 September 2011 from continuing operations are expected to be between 29% and 32% higher than the previous corresponding year's figure of 354.8 cents. The EPS and HEPS of the previous corresponding period were disclosed in the company's financial results for the six months ended 31 March 2011, released on SENS on 24 May 2011. Shareholders were reminded that a non tax-deductible International Financial Reporting Standards 2 ("IFRS 2") share-based payment expense of R269 million was incurred in the 2010 financial year (equivalent to 154.8 cents per share in that year), in relation to the Adcock Broad-Based Black Economic Empowerment Transaction approved in a general meeting of Adcock's shareholders on 9 April 2010. The company's financial results for the year ended 30 September 2011 will be released on SENS on 22 November 2011.
02-Aug-2011
(Official Notice)
Mr Andy Hall has been appointed deputy chief executive and financial director of Adcock Ingram with effect from 1 August 2011. In addition to fulfilling his function as the deputy chief executive, Mr Hall will oversee group finance, business development, corporate affairs, government relations and the company secretariat.
28-Jul-2011
(Official Notice)
Shareholders are referred to the announcement released by Adcock Ingram on 29th March 2011 relating to the acquisition of the business of Nutrilida Healthcare, ("NutriLida"), a vitamin, mineral and supplements ("VMS") business based in Johannesburg, South Africa (the "Transaction"). The Transaction was subject to the fulfilment or waiver, where applicable, of a number of conditions precedent which included the unconditional approval by the South African competition authorities. Adcock Ingram is pleased to announce that on 25th July 2011 the Competition Commission approved the Transaction without conditions. Shareholders are advised that all conditions precedent to the Transaction have been met, or where appropriate, waived by Adcock Ingram. The effective date of the Transaction will be 1st August 2011. =
24-May-2011
(Official Notice)
Reference is made to the announcement released on SENS on Tuesday, 24 May 2011. The website address of Adcock Ingram was incorrectly stated and should be www.adcock.com.
24-May-2011
(Official Notice)
Management of Adcock will be presenting the group interim results for the six-month period ended 31 March 2011 at an investor presentation. This presentation is available on the Adcock Ingram website at www.adcock.co.za.
24-May-2011
(C)
Revenue for the interim period ended 31 March 2011 increased by 13% to R2.221 billion (2010: R1.961 billion). Gross profit rose by 6% to R1.059 billion (2010: R994.9 million), operating profit grew by 1 % to R526.2 million (2010: R521.8 million), while net profit attributable to owners of the parent weakened to R353.4 (2010: R393.7 million). Furthermore, headline earnings per share from continued operations fell by 1% to 221.3cps (2010: 223.1cps).



Capital reduction out of share premium in lieu of interim dividend

The board has declared a capital reduction distribution (in lieu of an interim dividend) out of share premium of 81cps, payable to shareholders, in respect of the six months ended 31 March 2011.



Prospects

The integration of the Hospital and Pharmaceutical businesses has been slower than expected, but we foresee the integration gaining momentum in the second half of the year. The multinational partner of choice strategy has delivered attractive value as Adcock diversifies its revenue streams and decreases its dependence on mature products. They expect to extend the MNC partnerships as Adcock's expansion into sub-Saharan Africa continues. The group await the approval of the Competition Commission for the acquisition of NutriLida, with the decision expected within the next six weeks. The group maintains its focus on the acquisition of businesses and brands in high growth emerging markets as well as the acquisition of intellectual property that is globally relevant. Adcock is still awaiting MCC approval for key ARV registrations in South Africa, as well as several first-to-market generics. The MCC has not adequately addressed its capacity constraints which result in registration delays.
20-Apr-2011
(Official Notice)
Adcock shareholders were referred to the announcements released by Adcock on 10 December 2010 relating to the recommendation by the Medicines Control Council of the Department of Health ("MCC") to withdraw dextropropoxyphene ("DPP")-containing medicines from the South African market.



Shareholders were notified that Adcock would suspend all promotion and sales of DPP-containing products pending further interaction with the MCC and that Adcock Ingram would work with the MCC to formulate and execute a plan going forward to ensure continued safety of South African patients. The MCC later requested Adcock to prepare for a discussion with the Council on the safety of DPP and measures to be taken by healthcare providers. All the relevant documents were submitted to the MCC.



The MCC has considered comments received from Adcock at a recently held meeting and has resolved to withdraw the registration of all DPP- containing medicines within three months from the date of the notice, being 20 April 2011. Shareholders are advised that Adcock Ingram has a right to appeal the decision made by the MCC in accordance with section 24 of the Medicines and Related Substances Control Act 101 of 1965. The board of directors of Adcock has resolved to exercise that right and accordingly Adcock intends formulating and lodging an appeal with the MCC. Shareholders will be informed of further developments as necessary.
29-Mar-2011
(Official Notice)
Adcock announced the acquisition of the business of Nutrilida Healthcare, ("NutriLida") (the "transaction"), a vitamin, mineral and supplements ("VMS") business based in Johannesburg, South Africa. The acquisition of Nutrilida will further strengthen Adcock's position as the leader in the VMS market and increase its market share in the broader Fast Moving Consumer Goods ("FMCG") market.



Rationale

NutriLida has strong brands in several niche market segments. It is Adcock's intention to continue to grow these brands and leverage its brand building expertise to become a significant player in the South African VMS market. Adcock has grown its presence in the VMS category in recent years and has a strong presence in the tonics market with household name brands such as Bioplus, Vita-thion and Liviton. The transaction will strengthen Adcock's foothold in this fast growing market and further enable the group's strategy to gain market share in the FMCG category.



Details of the transaction

The sellers of the business of Nutrilida Healthcare are Nutrilida (Pty) Ltd, Midsummer Assets - Leasing (Pty) Ltd and Zeiss Road Manufacturing (Pty) Ltd ("the sellers"). The effective date of the transaction will be the last day of the month in which the last of the conditions precedent is fulfilled, which is anticipated to be no later than 31 July 2011. In terms of the purchase agreement entered into between the sellers and Adcock the purchase price is confidential.



Pro forma financial effects

Before - after the transaction:

* EPS (cents) : 363.5 - 381.3

* HEPS (cents) : 363.4 - 381.1

* NAV per share (cents) : 1 678.5 - 1 678.5.
23-Mar-2011
(Official Notice)
The company advised that Mr Ntando Simelane has been appointed as company secretary with effect from 1 April 2011.

18-Mar-2011
(Media Comment)
According to Business Report, Adcock is confident of securing more contracts with multinationals and more than doubling its liquid production as its R1.5 billion capacity building and accreditation programme speeds up. Adcock is working on increasing its liquids production of 8-9 million litres a year to about 24 million litres per annum and increasing volumes to other parts of Africa. In addition, CEO Jonathan Louw said the company's new and larger Durban facility would enable the business to reduce costs.
09-Feb-2011
(Media Comment)
Business Report indicated that Adcock Ingram planned to expand into West Africa this year, a move analysts said could be lucrative because of the region's population and growing economy. South Africa's second- largest drug firm already has a presence in Ghana through its 66.2% acquisition of Ayrton Drug Manufacturing, which was concluded last year. Adcock currently has 183 product registrations in the rest of Africa. This year the group anticipates registering 59 products and this is projected to reach 500 by 2015.
28-Jan-2011
(Official Notice)
Shareholders are advised that:

* Mr L.E. Schonknecht has resigned as chairman of the human resources, remuneration and nominations committee. However, he will continue to serve the board as an independent non-executive director and member of the risk and sustainability committee;

* Mr C.D. Raphiri, an independent non-executive director, will assume the role of chairman of the human resources, remuneration and nominations Committee; and

* Mr A.M. Thompson, an independent non-executive director, has been appointed to the human resources, remuneration and nominations committee. Mr Thompson remains a member of the audit committee and transformation committee. The changes set out above are effective 28 January 2011, and are being implemented inter alia to accommodate Mr Schonknecht's increased personal business commitments and executive responsibilities at his own company.
28-Jan-2011
(Official Notice)
Shareholders are referred to the announcement released by the company on SENS on 23 November 2010, regarding a formal sale agreement having been entered into in respect of the company's 74% holding in The Scientific Group (Pty) Ltd. Shareholders are advised that all conditions precedent to the transaction have been met, or where appropriate waived by the purchaser. The effective date of the transaction will be 1 February 2011. The financial effects of the transaction are not significant.
27-Jan-2011
(Official Notice)
Shareholders are advised that, at the AGM of the company held at 14h00 on Thursday, 27 January 2011, all of the special and ordinary resolutions set out in the notice to shareholders dated 24 December 2010 were passed by the requisite majority. The special resolution will be lodged with the Companies and Intellectual Property Registration Office for registration.
24 Dec 2010 09:38:38
(Official Notice)
Shareholders are advised that Adcock Ingram's 2010 annual report, containing the annual financial statements for the year ended 30 September 2010, has been posted to shareholders on 24 December 2010 and contains no modifications to the abridged audited results which were released on the Securities Exchange News Service of the JSE Limited ("SENS") on 23 November 2010.



The Company's auditors, Ernst - Young Inc, have audited the annual financial statements and their unqualified report is available for inspection at the Company's registered office. The annual report will be available on the Company's website www.adcock.com from 24 December 2010.



Notice is hereby given that the annual general meeting of the Company will be held on Thursday, 27 January 2011 at 14:00 at the Company's premises at 1 New Road, Midrand, Gauteng, to transact the business as stated in the notice of the annual general meeting.
14 Dec 2010 08:14:32
(Official Notice)
The results of the South African government's new antiretrovial (ARV) tender were announced on 13 December 2010, by national treasury. The total value of the State's ARV tender is R4.162 billion and the volume is 116.9 million units of tablets, capsules and liquid preparations. The term of the contract to provide these products is 1 January 2011 to 31 December 2012. Adcock has been awarded 4% of the tender by value, which amounts to R166.5 million, and 3.2% by volume for the two year period. The products awarded to Adcock are 60% of the total volume for Zidovudine 300mg tablets and 70% of the total volume for Efavirenz 50mg capsules. In June 2008, Adcock was awarded a value of R663 million for the supply of Efavirenz 600mg tablets for the period June 2008 to May 2010. The total value of the previous tender was R3.172 billion.
10 Dec 2010 17:06:42
(Official Notice)
Further to the announcement released on SENS, Adcock would like to advise that the Company has received notification from the Medicines Control Council of the Department of Health ("MCC") relating to the withdrawal of dextropropoxyphene ("DPP") containing medicines from the South African market. The notification confirms that the MCC has resolved that:

*all DPP containing medicines be withdrawn from the market;

*no new prescriptions of DPP containing medicines be allowed with immediate effect; and

*a three-month change-over period be permitted for patients who cannot be switched immediately to an alternate therapy.



Adcock has suspended all promotion and sales of DPP containing products pending further interaction with the MCC. Adcock Ingram will work with the MCC to formulate and execute a plan going forward to ensure continued safety of South African patients.
10 Dec 2010 08:06:38
(Official Notice)
On 19 November 2010, the US Food and Drug Administration ("FDA") withdrew dextropropoxyphene ("DPP") from the United States ("US") market. The FDA determined that the benefits of DPP for pain relief at US recommended doses outweighed the safety risk and as such the regulator requested that suppliers voluntarily withdraw any drugs containing DPP from the US market. Following the FDA announcement, Adcock engaged in discussions with the Medicines Control Council of the Department of Health ("MCC") relating to the implications of the US data to patient safety in South Africa. Adcock Ingram has now become aware that the MCC has resolved, inter alia, that all DPP containing medicines be withdrawn from the South African market. Adcock has not, as yet, received any formal communication from the MCC regarding withdrawal of its DPP containing medicines. DPP is a compound with pain-relieving properties that is found in three of Adcock's drugs, namely, Synap Forte, Lentogesic and Doxyfene. These drugs contributed approximately R200 million to Adcock's revenue for the financial year ended 30 September 2010.
23 Nov 2010 08:33:31
(C)
23 Nov 2010 08:14:18
(Official Notice)
Shareholders are advised that management of Adcock Ingram will be hosting a presentation to analysts on the Adcock Ingram Group results for the year ended 30 September 2010 today. The presentation will be available on the company's website at www.adcock.com from 08:30 a.m. today, 23 November 2010.
01 Nov 2010 15:02:00
(Official Notice)
Shareholders are advised that Adcock Ingram's normalised earnings per share and normalised headline earnings per share for the year ended 30 September 2010 are expected to be between 13% and 16% higher than the previous corresponding year taking into account the once-off share-based payment expense of R269 million incurred in the 2010 financial year, in relation to the Adcock Ingram's Broad- Based Black Economic Empowerment transaction approved in a general meeting of Adcock Ingram's shareholders on 9 April 2010. After accounting for the abovementioned expense, Adcock Ingram's earnings per share and headline earnings per share for the year ended 30 September 2010 are expected to be between 19% and 22% lower than the previous corresponding year. The company's results are expected to be released on SENS on Tuesday, 23 November 2010.
08 Oct 2010 10:01:50
(Official Notice)
Reference is made to the announcements released by the company on SENS, the latest dated 14 September 2010, regarding the initiation by Baxter of the call option process contained in the agreement between, inter alia, Baxter, Adcock and Adcock Ingram Critical Care dated 17 July 2008 ("the Option Agreement"). A dispute ("the dispute") arose between Baxter and Adcock Ingram following receipt of the written report prepared by KPMG Services (Pty) Ltd dated 12 July 2010 regarding the price at which Baxter would be entitled to exercise the call option ("call option"). Shareholders were advised that Adcock Ingram and Baxter had agreed to submit the dispute to arbitration, due to be held in February 2011.



Outcome of call option process

For strategic reasons unrelated to the business of AICC, Baxter has elected not to proceed with the exercise of the call option. Consequently, it is no longer necessary to resolve the dispute or to continue with the arbitration process. The Option Agreement has therefore been cancelled by mutual agreement of the parties. The business of AICC will continue under the control of Adcock and will continue to benefit from the existing licence, distribution and raw materials supply agreements with Baxter.



Withdrawal of cautionary

Accordingly, shareholders are advised that the cautionary has been withdrawn.
14 Sep 2010 09:03:01
(Official Notice)
Reference was made to the various announcements released by the company on SENS, the latest being 2 August 2010, relating to the call option process initiated by Baxter in terms of the agreement between, inter alia, Baxter, Adcock Ingram and AICC dated 17 July 2008 ("the option agreement"). A dispute has arisen between Baxter and Adcock Ingram as to what the price is at which Baxter may exercise the call option in the option agreement ("call option"), having regard to the written report dated 12 July 2010 prepared by KPMG Services (Pty) Ltd. Shareholders were advised that the parties to the option agreement have agreed to submit the dispute to arbitration. The arbitration is due to be heard in February 2011. The option agreement has been amended such that, inter alia, Baxter will be entitled to exercise the call option within a period of three weeks following the earlier of the date on which:

* Adcock Ingram and Baxter agree in writing on the "fair market value determination" (as that term is defined in the option agreement) in respect of the shares in AICC which are the subject of the call option;

* and the arbitrators give their written award in the arbitration.



Cautionary

Accordingly, shareholders were advised to continue exercising caution when dealing in Adcock Ingram securities until a further announcement was made.
03 Sep 2010 09:11:24
(Official Notice)
Adcock hereby advises that Ms Ramani Naidoo has tendered her resignation as company secretary with effect from 7 September 2010. An announcement will be made once the new company secretary is appointed.
02 Sep 2010 08:33:12
(Media Comment)
Business Day reported that Adcock Ingram, SA's second- biggest pharmaceutical manufacturer, has expanded its five-year co-promotion and distribution agreement with world's second- biggest drug firm, US- based Merck - Co (MSD) beyond SA's borders to include six other African countries. Adcock will expand its portfolio of products, while MSD hopes to increase sales in key African markets by leveraging off Adcock's presence there. The expanded deal includes Botswana, Namibia, Swaziland, Lesotho, Kenya, and Ghana. Marc Princen, MSD's president commented that there is a lot attention today on Brazil, China, and India, but he believes that the next set of emerging markets will be on the African continent.
12 Aug 2010 17:38:05
(Official Notice)
At the special general meeting of Adcock shareholders held on Thursday, 12 August 2010, the ordinary resolution proposed was duly passed by the requisite majority of votes cast by shareholders present and voting at the special general meeting.

02 Aug 2010 15:32:24
(Official Notice)
Update on the call option process initiated by Baxter Healthcare SA ("Baxter") in respect of Adcock Ingram Critical Care (Pty) Ltd ("AICC") and further renewal of cautionary announcement Reference is made to the various announcements released by the company on SENS, the latest being 21 June 2010, regarding the call option process initiated by Baxter in terms of the agreement between, inter alia, Baxter, Adcock and AICC dated 17 July 2008 ("the option agreement").



In an earlier announcement released by the company on SENS on 25 May 2010, shareholders were advised that Baxter and Adcock had been unable to agree the value of the call option shares (namely, 50% plus one share of AICC's issued share capital) ("the call option shares") on the basis prescribed by the option agreement and had therefore referred the determination thereof to an independent expert, KPMG Services (Pty) Ltd ("KPMG"). Adcock Ingram is of the view that such determination was to be made by KPMG on the basis prescribed by the option agreement.



The company has now received KPMG's final valuation report in respect of the call option shares ("KPMG Report"). KPMG has determined two values. In Adcock Ingram's view, these are, one in terms of the formula prescribed by clause six of the option agreement and one based on discounted cash flows supported by secondary methodologies. Baxter disagrees with Adcock's views including Adcock's view in respect of the value that should apply for the purposes of the exercise by Baxter of the call option in respect of the call option shares ("call option"). Baxter has yet to exercise the call option and Adcock Ingram is in the process of obtaining legal advice on its rights under the option agreement regarding the different views. In the interim, Baxter has engaged Adcock in regard to possible resolution of the issue. Accordingly, shareholders are advised to continue exercising caution when dealing in Adcock securities until a further announcement is made.
24 Jun 2010 07:58:00
(Official Notice)
Shareholders are advised that Adcock Ingram has entered into a five-year strategic collaboration to co-promote and distribute a number of established MSD products. MSD is a trade name of Merck - Co., Inc. ("Merck"), with headquarters in Whitehouse Station, New Jersey, USA. The MSD products that will be co- promoted by MSD and Adcock Ingram include MSD's over-the-counter products currently registered in South Africa and selected prescription medicines.



MSD is a global healthcare leader with a presence in more than 140 countries and is currently ranked number 8 in South Africa in a survey conducted by IMS Health, the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. The collaboration between MSD and Adcock will be managed by a Joint Operating Committee consisting of management members of both companies.



The financial effects of the transaction are not material. Adcock Ingram shareholders are advised that the cautionary announcement dated Monday, 21 June 2010 relating to this transaction is withdrawn. Adcock Ingram shareholders should, however, note that Adcock is still trading under cautionary as a result of the transaction relating to the initiation of the call option process by Baxter Healthcare SA and should continue to exercise caution when dealing in Adcock Ingram securities until a further announcement is made.
21 Jun 2010 17:20:03
(Official Notice)
Shareholders are referred to the cautionary announcement dated 8 February 2010 and the renewal of cautionary announcements dated 23 March 2010 and 7 May 2010 relating to the formal notification received by the company from Baxter of its intention to initiate the call option process as set out in the agreement between, inter alia, Baxter, Adcock and AICC dated 17 July 2008. Shareholders are advised that:

*the terms of the Baxter and Adcock Ingram shareholders' agreement as contemplated in terms of the option agreement, have been agreed in principle (subject to below); and

*the only issue that remains outstanding is the independent expert valuation to determine the fair market value of AICC.



Further announcements will be published in due course.



Cautionary announcement

Shareholders are advised that the company has entered into negotiations relating to a marketing and distribution arrangement. The directors of Adcock are confident that the successful conclusion of these negotiations will have a beneficial effect on the future direction of Adcock. Accordingly, shareholders are advised to continue exercising caution when dealing in Adcock securities until further announcements are made.
10 Jun 2010 09:07:22
(Official Notice)
Adcock shareholders are referred to the announcement released on SENS on 9 April 2010 relating to the adjournment of the general meeting of Adcock shareholders ("the adjourned general meeting") and the notice of general meeting dated 17 March 2010 ("the notice of general meeting").



Shareholders are informed that the board of directors of Adcock has resolved to withdraw the special resolution contained in the notice of general meeting and this being the only resolution to be proposed at the adjourned meeting, such adjourned meeting has been cancelled.
25 May 2010 08:08:34
(C)
25 May 2010 07:38:00
(Official Notice)
Management of Adcock will be presenting the Adcock Group interim results for the six-month period ended 31 March 2010 at an investor presentation today. This presentation contains additional disclosures to those made in the interim results announcement released on SENS and is available on the Adcock website at wwww.adcock.co.za.
07 May 2010 15:33:42
(Official Notice)
Shareholders are referred to the cautionary announcement dated 8 February 2010 and the renewal of cautionary announcement dated 23 March 2010 relating to the formal notification received by the company from Baxter of its intention to initiate the call option process as set out in the agreement between, inter alia, Baxter, Adcock Ingram and AICC dated 17 July 2008.



Shareholders are advised that:

* Baxter has completed its due diligence investigation in terms of the option agreement;

* Baxter and Adcock Ingram are in the process of finalising the shareholders' agreement contemplated in terms of the option agreement; and

* Baxter and Adcock have commenced discussions regarding the basis for determining the fair market value of AICC as set out in the option agreement.



Shareholders are therefore advised to continue exercising caution when dealing in Adcock Ingram securities until a further announcement is made.
09 Apr 2010 14:27:31
(Official Notice)
Adcock shareholders are referred to the notice of general meeting dated 17 March 2010, in terms of which a general meeting of Adcock ordinary shareholders was convened to be held at 10:00 on 9 April 2010, or as soon as the general meeting convened to consider the Adcock Broad Based Black Economic Empowerment Transaction was concluded.



This general meeting was declared duly constituted and was then adjourned by the chairman, with the consent of the meeting. Consent was given for such adjournment to allow further shareholder engagement on the resolution and to clarify certain technical legal issues arising from the framing of the resolution as a special resolution. Adcock shareholders will be advised of the date of the reconvened meeting by way of an announcement to be released on SENS in due course.
09 Apr 2010 10:55:24
(Official Notice)
At the general meeting of Adcock ordinary shareholders held on 9 April 2010 in relation to the black economic empowerment transaction to be undertaken by Adcock, all of the ordinary and special resolutions required to authorise the implementation of the transaction as set out in the notice of the general meeting were duly passed by the requisite majority of votes. The special resolutions will be lodged for registration with CIPRO as soon as possible. Once the special resolutions have been lodged with CIPRO, all conditions precedent to the implementation of the transaction would be fulfilled.
01 Apr 2010 14:02:15
(Official Notice)
Fulfilment of conditions relating to the offer to acquire at least 51% of the entire issued share capital of Ayrton Drug Manufacturing Ltd. Further to the announcement dated 5 March 2010, Adcock Ingram hereby advises holders of ordinary shares in Adcock that the general conditions in paragraph 1 of Part VIII of the offer document dated 3 February 2010 and the suspensive conditions set out in paragraph 2 of Part VIII of the offer document have been fulfilled and/or waived by Adcock Ingram. The offer is accordingly unconditional in all respects and closed for acceptances on 29 March 2010. Pursuant to the offer Adcock acquired 65.59% of the entire issued share capital of Ayrton. Shareholders are referred to the full text of the announcement below which was released in Ghana today.
23 Mar 2010 13:08:19
(Official Notice)
Shareholders are referred to the cautionary announcement dated 8 February 2010 relating to the formal notification received by the company from Baxter of its intention to initiate the call option process as set out in the agreement between, inter alia, Baxter, Adcock Ingram and AICC dated 17 July 2008. Shareholders are advised that Baxter is currently conducting a due diligence investigation in terms of the option agreement. Shareholders are therefore advised to continue exercising caution when dealing in Adcock Ingram securities until a further announcement is made.
16 Mar 2010 08:07:38
(Official Notice)
05 Mar 2010 17:07:01
(Official Notice)
Further to the announcement dated 19 February 2010, Adcock hereby advise holders of ordinary shares in Adcock ("Adcock shareholders") of the announcement set out below, released today 5 March 2010 in Accra, Ghana. As at the time of this announcement, acceptances had been received in respect of 54.6% of the entire issued ordinary share capital of Ayrton. Adcock shareholders will be kept informed of the progress in regard to this transaction by way of further announcements on SENS.



Adcock Ingram hereby notifies all shareholders of Ayrton ("Ayrton Shareholders") that the suspensive conditions set out in paragraph 2 of Part VIII of the offer document dated 3 February 2010 ("Offer Document") have been fulfilled and/or waived by Adcock Ingram. The offer is accordingly only subject to the general conditions set out in paragraph 1 of Part VIII of the Offer Document which must be fulfilled and/or waived on or before the Offer Expiration Date (set out in the table below). As at the time of this announcement on Friday 5 March 2010, acceptances had been received in respect of 54.6% of the entire issued ordinary share capital of Ayrton.

*Ayrton Shareholders who wish to accept the offer and have not already done so must complete and return the Form of Acceptance to First Atlantic Brokers by not later than 17:00 hours GMT on March 29, 2010.

*Acceptance Period: 9:00 hours GMT on February 15, 2010 - 17.00 hours GMT on 29 March 2010.

*Offer Expiration Date : 17:00 hours GMT on 29 March 2010.

*Settlement Date :1 April 2010 .

*Announcement of Offer Results : 1 April 2010.
19 Feb 2010 17:45:11
(Official Notice)
Further to the announcement dated 23 November 2009, Adcock hereby advised holders of ordinary shares in Adcock ("Adcock shareholders") that the document containing the conditional offer by Adcock, on behalf of Adcock Ingram International (Pty) Ltd, to the holders of the issued ordinary shares in Ayrton ("Ayrton shareholders") to acquire at least 51% of the entire issued ordinary share capital of Ayrton at a price of GH cents (USD) 0.16 per Ayrton share ("the offer") has been posted to Ayrton shareholders. The offer opened on Monday, 15 February 2010 and expires on Monday, 29 March 2010. The board of directors of Ayrton has approved the offer and has recommended that Ayrton shareholders accept the offer.



Further announcements

Adcock shareholders will be kept informed of the progress in regard to this transaction by way of further announcements on SENS.
18 Feb 2010 12:45:17
(Official Notice)
Shareholders are referred to the further cautionary announcement released on SENS on 7 January 2010 and the detailed cautionary announcement released on SENS on 24 November 2009, in which Adcock announced the key terms of the Transaction, which will facilitate the introduction of additional BEE equity participation in Adcock. A further announcement will be released on SENS and published in the press once the full terms, the salient dates and the financial effects of the Transaction have been finalised. Accordingly, Adcock shareholders are advised to continue to exercise caution when dealing in Adcock securities, until a further announcement is made.
10 Feb 2010 11:37:43
(Media Comment)
Adcock Ingram would use the proceeds from the sale of a multibillion-rand 51% stake in it's critical care division to fund it's growth strategy which has seen it make acquisitions both locally and in other parts of Africa, Mike Mabasa, a spokesman for the pharmaceutical firm, said yesterday. This week, the drug company said the Swiss multinational Baxter Healthcare had notified it of an intention to exercise a call option to acquire 51% of the critical care division, which supplies mainly hospital products.

08 Feb 2010 17:00:39
(Official Notice)
Shareholders are advised that the company has received formal notification from Baxter of its intention to initiate the call option process as set out in the agreement between, inter alia, Baxter, Adcock Ingram and AICC dated 17 July 2008, the salient terms of which were disclosed to Adcock Ingram shareholders in section 2.5.2 of the company's pre-listing statement dated 29 July 2008.

In terms of the option agreement, Baxter would be entitled to acquire 51% of the shares in AICC pursuant to completion of a due diligence of AICC and agreeing a fair market valuation with Adcock Ingram, in terms of a defined valuation methodology. In terms of the notice, Baxter shall now proceed to carry out a valuation of AICC and request certain due diligence information. The valuation and regulatory approval processes are expected to take at least four months, and may possibly continue for the remainder of the calendar year.



Shareholders are therefore advised to exercise caution when dealing in Adcock Ingram securities, until a further announcement is made.
03 Feb 2010 17:38:52
(Official Notice)
Shareholders are advised that at the annual general meeting ("AGM") of Adcock Ingram, all the resolutions proposed were passed by the requisite majority of votes cast by shareholders present and voting at the AGM, save for special resolution 1 relating to the proposed remuneration payable to non-executive directors. Voting in respect of Special resolution 1 was as follows: In favour 73.51%; Against 26.16%; Abstentions 0.32%. Ordinary resolution 4 relating to the authority to place 5% of the total number of issued ordinary shares in the share capital of the company under the control of the company's directors and ordinary resolution 5 relating to a general authority to issue shares for cash were withdrawn prior to voting commencing and were not voted upon. The special resolution approved by shareholders will be lodged with the Companies and Intellectual Property Registration Office of South Africa for registration, as required by law.
28 Jan 2010 08:47:03
(Media Comment)
Business Report noted that Adcock will consider further expansions into the east Africa region following the company's so far successful entry into Kenya. Adcock spokesman Mike Mabasa said there are a number of opportunities in East Africa, including public sector tenders and the launching of consumer products in markets in which Adcock does not operate yet.
07 Jan 2010 07:14:46
(Official Notice)
Shareholders are referred to the detailed cautionary announcement released on SENS on 24 November 2009, in which Adcock announced the key terms of the Transaction, which will facilitate the introduction of additional BEE equity participation in Adcock. A further announcement will be published on SENS and in the press once the full terms, the salient dates and the financial effects of the transaction have been finalised. Accordingly, Adcock shareholders are advised to continue to exercise caution when dealing in their Adcock shares, until a further announcement is made.
18 Dec 2009 13:26:25
(Official Notice)
Shareholders are advised that the company's 2009 annual report, containing the annual financial statements for the year ended 30 September 2009, has been posted to shareholders on 18 December 2009 and contains no modifications to the abridged audited results which were released on SENS on 24 November 2009. The company's auditors, Ernst - Young Inc, have audited the annual financial statements and their unqualified report is available for inspection at the company's registered office. The annual report will be available on the company's website www.adcock.co.za from 21 December 2009.



Notice is hereby given that the annual general meeting of the company will be held on Wednesday, 3 February 2010 at 14:00 at the company's premises at 1 New Road, Midrand, Gauteng, to transact the business as stated in the notice of the annual general meeting.

27 Nov 2009 08:54:10
(Media Comment)
Business Report noted that Ghana's Ayrton Drug Manufacturing has approved Adcock's bid for the company. Adcock will acquire at least 51% of the company's shares and will have to pay R178.4 million.
24 Nov 2009 08:38:30
(Official Notice)
24 Nov 2009 08:25:56
(C)
Revenue more than doubled to R4.1 billion (R1.8 billion). Gross profit surged to R2 billion (loss of R0.8 billion) and net attributable profit rose by more than 100% to R782.4 million (R318.4 million). In addition, headline earnings grew to 450cps (195.6cps).



Dividend

A final ordinary dividend of 80cps has been declared.



Outlook

Whilst current economic conditions remain challenging, particularly at a consumer level, Adcock expects further volume growth in its core businesses. Gross margin should be maintained while the rand remains at current levels. On the regulatory front, Adcock awaits the outcome of the NHI advisory committee to the Minister of Health during the course of 2010. The group also notes the issuance of the Government Gazette in late October detailing the mechanics of the SEP increase for 2010 and the amended dispensing fee for pharmacists. Management looks forward to achieving success for Adcock in the various government tenders in both the Pharmaceutical and Hospital Products division and remain committed to supporting government in its rollout of ARVs. Adcock continues to seek opportunities to access other high growth emerging markets and expects to diversify its earnings beyond the borders of South Africa. The company will leverage the capacity in its efficient supply chain, product pipeline and competence in brand building in these markets and Adcock is well placed for acquisitive growth given our significant financial capacity.
23 Nov 2009 17:33:08
(Official Notice)
07 Oct 2009 09:33:13
(Media Comment)
Adcock is investigating expansion opportunities in India and east Africa, reported Business Day. The company is also planning to boost its fast-moving consumer goods portfolio. Adcock is seeking new revenue streams after failing to acquire rival Cipla Medpro South Africa Ltd.
22 Sep 2009 16:21:29
(Official Notice)
Shareholders are referred to the SENS announcement released by Tiger Brands Ltd, which advised that Tiger Brands was launching an accelerated bookbuild placing of 10 326 758 ordinary shares of Adcock Ingram to international and South African institutional investors. Pursuant to the unbundling of Adcock Ingram by Tiger Brands, effective from 1 September 2008, Tiger Consumer Brands Ltd ("TCB"), a wholly-owned subsidiary of Tiger Brands, acquired 8 589 328 Adcock Ingram ordinary shares as a consequence of TCB holding Tiger Brands ordinary shares as treasury shares. In terms of the unbundling agreement between Adcock Ingram and Tiger Brands dated 17 July 2008, and as mentioned in the Adcock Ingram pre-listing statement dated 24 July 2008, Adcock Ingram has a pre-emptive right over the legacy shares. Adcock Ingram confirms that it was approached by Tiger Brands in regard to its pre-emptive right prior to Tiger Brands embarking on the accelerated bookbuild. Having carefully considered the price at which Tiger Brands offered the legacy shares to Adcock Ingram, and taking into account the company's stated strategic imperatives, Adcock Ingram decided not to exercise the pre-emptive right as it would not be an optimal allocation of Adcock Ingram's capital at this time.
03 Jul 2009 08:56:37
(Official Notice)
Further to the release of the results of Adcock Ingram for the 6-month period ended 31 March 2009, wherein Adcock Ingram advised that it received approval from the Department of Trade and Industry for a capital expenditure project in the Pharmaceutical division to qualify as a strategic industrial project. The Strategic Industrial Project programme is an incentive programme which was designed to encourage investments into South African industry operations from both local and foreign investors. Its primary aim is to significantly contribute to growth, development and competitiveness of specific industry sectors by providing industrial investment allowances, in the form of tax relief, to qualifying industrial projects.



The SIP programme is governed by section 12G of the Income Tax Act No 58 of 1962.The company will qualify for a special tax allowance of R458 million, equating to a tax saving, at current tax rates, of R128 million over a period of four years.



Adcock Ingram has embarked on the approved capital project and will make its first tax claim under this special dispensation for the tax year ended 30 September 2009. Adcock Ingram expects to fully utilise the special allowance within three years, thereby resulting in an accelerated tax saving.
11 Jun 2009 09:26:08
(Media Comment)
Despite missing out on Ciplamed, the Financial Mail wrote that Adcock has not scaled back its ambitious expansion plans. CEO Jonathon Low is spreading the business across Africa and entering "adjacent areas" like the customer wellbeing sector. In addition, Louw is also looking at West Africa. At the moment Africa only accounts for R100 million of Adcock's annual revenue or R3.3 billion, but Louw is confident that this can be increased. The company is already in Kenya and Zimbabwe.
02 Jun 2009 07:51:27
(Official Notice)
Adcock has resolved not to proceed with its offer for Cipla Medpro South Africa Ltd ("Ciplamed").



Withdrawal of cautionary

As a result, it is no longer necessary for Adcock shareholders to exercise caution in dealing in their Adcock shares.
02 Jun 2009 07:39:49
(C)
Maiden interim results as a listed company showed turnover was R1.9 billion on the back of strong volume growth from the anti-retroviral (ARV) tender awarded in the second half of the previous financial year, and reasonable volume growth in the hospital segment. Gross profit amounted to R935 million with margins declining from 57% to 49%. Net profit for the period attributable to ordinary shareholders came in at R354.9 million. In addition, headline earnings on a per share basis was 204.8cps.



Dividend

An interim ordinary dividend of 70cps has been declared.



Outlook

It is difficult to forecast with confidence while meaningful regulatory uncertainty prevails. Adcock has, however, been encouraged by the process and the timing applied by the department of health in the most recent adjustments to SEPs. These adjustments will offset in the balance of the financial year some of the exchange rate impacts that are reflected in the half year results. Adcock expects the further interest reductions announced by the Reserve Bank to flow through to improved spending on discretionary items in its portfolio, in OTC and personal care categories.
11 May 2009 13:05:34
(Media Comment)
According to Finweek, Adcock CEO Jonathon Louw has a touch decision to make concerning the company's bid for Cipla Medpro South Africa Ltd ("Ciplamed"). If Adcock walks away from its proposed takeover Ciplamed, Louw's credibility could be in doubt. However, if Louw sticks to the bid and Ciplamed's Indian supplier, Cipla India, cancels its supply agreement, the deal will lose its main motivation. Another stumbling block to the deal is the strong relationship between Ciplamed CEO Jerome Smith and Cipla India. Adcock and Louw seem to have underestimated it.
06 May 2009 14:11:05
(Official Notice)
Adcock is surprised that Cipla India, as a principal supplier to CMSA but not a shareholder, has decided to comment on a potential transaction affecting CMSA, without first waiting for the board of directors of CMSA to express a view on the merits of the proposed offer. Adcock is also surprised that Cipla India does not recognise the clear benefits for them in the proposed transaction, as contemplated in the firm intention announcement released on SENS on 9 April . The board of directors of Adcock ("Adcock Board") continues to believe strongly that:

*The strategic rationale for combining the two companies is compelling and would be in the best interests of all stakeholders, including Cipla India.

*The proposed combination will drive efficiencies and deliver revenue and cost synergies that neither company could extract on a standalone basis.

*The proposed offer consideration of R4.75 per CMSA share is a full and fair price, a view supported by the substantial support Adcock has already received from significant institutional CMSA shareholders.

*All CMSA shareholders should be afforded the opportunity to decide on the commercial merits and benefit from the proposed offer.



Adcock 5 May 2009, received confirmation that the SRP has given its consent, as requested by Adcock, to any non-compliance with Rule 27.1 of the Securities regulation code on takeovers and mergers as may arise from Adcock proceeding with the proposed offer, as contemplated in the firm intent announcement.
04 May 2009 17:57:01
(Official Notice)
Adcock shareholders are referred to the SENS announcement released by Ciplamed on 4 May 2009. Specifically, Adcock shareholders' attention is drawn to the "Unequivocal rejection letter from Cipla Ltd ("Cipla India")" purported to have been sent to Dr J Louw on 21 April 2009. Adcock shareholders are hereby notified that neither Dr Louw nor anyone else at Adcock received nor are currently in possession of any such letter.



Adcock has already received undertakings from Ciplamed shareholders holding 36.13% of the entire issued share capital of Ciplamed. Adcock believes the remaining CMSA shareholders should be afforded the opportunity to decide on the commercial merits of the proposed offer. Adcock has made submissions to the SRP regarding the granting of consent to any non-compliance with Rule 27.1 of the Securities Regulation Code on Takeovers and Mergers as may arise from Adcock proceeding with the proposed offer, as contemplated in the firm intent announcement released on SENS on 9 April 2009. The SRP has confirmed that no objections were received by the specified deadline. Adcock is accordingly confident that the SRP will shortly grant the consent requested by Adcock, and Adcock will make a further announcement in this regard in due course.



On 29 April 2009, the Competition Commission granted its permission in respect of Adcock's application. Adcock intends to file a separate merger notification imminently. Adcock welcomes the establishment of an independent subcommittee of the board of directors of Ciplamed to consider the proposed offer. Adcock shareholders are advised to continue to exercise caution when dealing in their Adcock securities until such time as a further announcement is made.
24 Apr 2009 15:49:08
(Official Notice)
Since the release of Adcock's firm intention announcement on SENS on 9 April 2009 and the publication thereof in the press on 14 April 2009, Adcock has secured further irrevocable undertakings from Visio Capital Management (Pty) Ltd, RMB Asset Management (Pty) Ltd and Investec Asset Management (Pty) Ltd. These further undertakings together with the irrevocable undertakings from Stanlib Asset Management Ltd, Allan Gray Ltd and Sanlam Investment Management (Pty) Ltd and Sanlam Investment Management (a division of Sanlam Life Insurance Ltd), as mentioned in the firm intention announcement, mean that the aggregate number of Cipla Medpro South Africa Ltd ("Ciplamed") shares subject to the undertakings referred to herein amounts to 160 155 349 Ciplamed shares, representing 36.13% of the entire issued share capital of Ciplamed.



Further announcements will be made by Adcock during the first week of each calendar month, commencing in June 2009 and ending with the proposed announcement on the day prior to the posting of the scheme circular or offer circular to Ciplamed shareholders.
16 Apr 2009 09:03:26
(Media Comment)
The proposed acquisition of Cipla Medpro South Africa Ltd ("Ciplamed") by Adcock may not materialise, according to the Financial Mail. Nevertheless, Adcock CE Jonathon Louw says a tie-up will unlock synergies. Adcock still needs approval from the Competition Commission and has approached Ciplamed for a joint submission.
15 Apr 2009 07:43:28
(Official Notice)
On 9 April 2009 Adcock announced its firm intention to make an offer to acquire the entire issued share capital of Cipla Medpro South Africa Ltd. During the webcast presentation that took place after the announcement was released, Andy Hall, chief financial officer of Adcock, referred to the "certain funds events" summarised in the announcement dated 9 April 2009. The specific certain funds events referred to are set out in summary form below:



"8.2.3 a reduction in the consolidated earnings before interest, tax, depreciation and amortisation ("EBITDA") of Adcock for the most recently completed rolling 12-month period (as set out in the most recent consolidated management accounts of Adcock) to 90% or less of the pro forma EBITDA of Adcock for the 12-month period ended 30 September 2008 of R1 073 214 000; and 8.2.4 a reduction in the shareholders' funds of Adcock ("NAV"), as determined in accordance with International Financial Reporting Standards (as set out in the most recent consolidated management accounts of Adcock), to 90% or less of the NAV of Adcock as at 30 September 2008 of R1 628 391 000;"



Andy Hall commented, with reference to the item at 8.2.3 above, that "those of you who look at us closely will remember that that was R1.073 billion at the EBITDA level. You will see our results posted in June, so we can tell you that it's unlikely that that's going to happen." With reference to the item at 8.2.4 above, Andy Hall commented "Clearly that event is extremely unlikely, because we would need to be making losses for that to happen."
09 Apr 2009 07:51:16
(Official Notice)
08 Apr 2009 08:51:13
(Media Comment)
Business Day reported that Adcock has acquired fast-moving consumer goods company Tender Loving Care ("TLC") for an undisclosed amount. TLC operates in the supplements and personal care market, a market in which Adcock would like to grow its presence.
06 Mar 2009 17:25:15
(Official Notice)
Adcock is pleased to announce that it intends pursuing a transaction that will culminate in the introduction of BEE equity participation in Adcock. Adcock is committed to transformation through the introduction of broad-based BEE equity partners into the business to add to the significant progress it has made in the areas of, inter alia, employment equity, skills development, preferential procurement and enterprise development. The transaction will be implemented as part of Adcock's committed efforts to achieve the objectives set out in the Department of Trade and Industry's Codes of Good Practice and will take cognisance of the future requirements of a Healthcare Charter. Participants in the transaction will include Adcock's staff and strategic shareholders (including broad-based BEE groupings). In this regard, Adcock intends identifying prospective broad-based BEE equity partners with experience and expertise in the healthcare industry that can add value and assist Adcock in achieving its strategic and growth objectives. Adcock shareholders are referred to the press announcement that will be published in the Sunday Times and City Press of Sunday, 8 March 2009 and in the Business Day and The Sowetan on Monday, 9 March 2009 (which will also be available on its website www.adcock.com) calling for expressions of interest from black groups as part of the external partner selection process. Further announcements with regards to progress of the proposed BEE transaction will be made in due course.
28 Jan 2009 16:10:37
(Official Notice)
Shareholders are advised that, at the annual general meeting of Adcock held on Wednesday, 28 January 2009, all resolutions were passed by the requisite majority of votes cast by shareholders present and voting at the meeting.
22 Dec 2008 14:15:32
(Official Notice)
Shareholders are advised that Adcock's annual report, containing its financial statements for the year ended 30 September 2008 and the notice of the annual general meeting, have been issued to holders of securities and the JSE Limited on 17 December 2008. An abridged report will not be published as the audited financial results published on SENS on 2 December 2008 remain unchanged. The annual general meeting of members of Adcock will be held at 15h00 on 28 January 2009 at the company's premises at 1 New Road, Midrand, Gauteng.
02 Dec 2008 08:07:44
(C)
Adcock's maiden results as a listed company showed revenue of R1.8 billion. Net profit attributable to ordinary shareholders amounted to R318.4 million and headline earnings on a per share basis of 195.6cps was recorded.



Dividend

The Adcock board intends to declare a dividend on at least an annual basis, and it currently envisages that the total annual dividend will be covered three times by headline earnings. As disclosed in the pre-listing statement, the maiden dividend is expected to be declared based upon the results of the six- month period ending 31 March 2009, as the final dividend payable by Tiger Brands Ltd in relation to the year ended 30 September 2008 includes the earnings of Adcock for five months of the six-month period.



Prospects

While Adcock anticipates an uncertain regulatory environment, continued currency volatility and a slowdown in the South African economy in the year to come, management remains committed to growing Adcock, organically and by prudent acquisition, into a leading world-class branded healthcare company that creates value for shareholders.
01 Dec 2008 14:58:43
(Official Notice)
The board of Adcock Ingram wishes to announce the resignation of Dr GN Padayachee as non-executive director of Adcock Ingram with effect from 1 December 2008. Dr Padayachee has decided to take up a senior appointment within the Department of Health. In the best interests of the company and in accordance with good corporate governance Dr Padayachee has decided to relinquish his post as non-executive director of Adcock Ingram to avoid any potential conflict of interests.





26 Nov 2008 09:45:33
(Official Notice)
Shareholders are referred to the year end results announcement of Tiger Brands Ltd ("Tiger Brands") for the year ended 30 September 2008 released on SENS on Tuesday, 25 November 2008. The announcement stated that results of Adcock for the eleven months to 24 August 2008 were included in Tiger Brands' results (under the heading "discontinued operations") following the unbundling of Adcock, which was completed on 25 August 2008. Shareholders are advised that the Tiger Brands results may contain certain consolidation adjustments which may not necessarily be accounted for in the same manner by Adcock as a separate group and should therefore not be viewed as an indication of Adcock's full year results.



As a result of the unbundling of Adcock on 29 August 2008, the 2008 results disclosed above include only eleven months of trading of Adcock compared to a full year's trading in 2007. Furthermore, shareholders should note that the extract from Tiger Brands' results containing the results of Adcock were not reviewed or audited by Adcock's auditors. Adcock's results for the year ended 30 September 2008 are expected to be released on SENS on or about Tuesday, 2 December 2008. Shareholders are advised to await the publication of the Adcock results before making an informed opinion of the results.
04 Nov 2008 07:16:21
(Media Comment)
According to Business Report, Adcock and other local pharmaceutical firms, are investigating a number of ways to mitigate the adverse affect of the global financial crisis. Adcock CFO, Andy Hall, said that any depreciation in the rand directly affects the profitability of the sector. However, Hall also commented that Adcock was hedging against exchange rate volatility with forward contracts. Nevertheless, its Indian joint venture was also been affected by a weakening rupee. This did not mean that any capital projects had been postponed, but they were been continuously re-evaluated.
15 Oct 2008 11:04:48
(Official Notice)
Adcock shareholders are referred to the announcement and circular to shareholders dated 22 September 2008 in terms of which shareholders were informed that a meeting of shareholders had been convened to be held on Wednesday 15 October 2008 in order to consider and approve resolutions in terms of which the board of Adcock would be granted the authority to:

*exercise the pre-emptive right in terms of which Adcock (or any designated wholly-owned subsidiary of Adcock) may acquire a maximum of 8 589 328 Adcock ordinary shares presently held by Tiger Consumer Brands Limited on the terms and subject to conditions relating thereto in the unbundling agreement concluded between Tiger Brands Limited and Adcock dated 17 July 2008 should the relevant situation arise; and

*repurchase Adcock ordinary shares in terms of a limited general authority should the Board of Adcock consider it appropriate in the circumstances.

The special and ordinary resolutions proposed at the general meeting were all passed by the requisite majorities. The special resolutions will be lodged with the Registrar of Companies for registration as soon as possible.
22 Sep 2008 15:30:09
(Official Notice)
26 Aug 2008 10:21:41
(Media Comment)
Business Day reported that Adcock's return to the JSE as a listed company disappointed, with the shares trading below expectations. The stock listed at R35.00, touched an intra-day high of R36.00 and a low of R30.00, before closing down at R34.05.
08-Apr-2015
(X)
Product ranges:

Consumer and Over-the-Counter products constitute the largest segment of the company business in South Africa. Market-leading brands such as Panado have put the company in a leadership position in the private pharmacy market and the fast moving consumer goods (FMCG) segment.



The Prescription Medicines portfolio comprises a range of quality and affordable generic medicines which includes a comprehensive range of antiretroviral medicines (ARVs), including the triple therapy combination. Partnerships with multinational pharmaceutical companies continue to augment the comprehensive portfolio of originator medicines marketed by the company.



The Critical Care portfolio has a long history in the company based on an agreement with Baxter and positions Adcock Ingram as the leading supplier in critical care products to the private and public sectors.



Local Manufacturing:

Adcock Ingram has recently undertaken a capital expansion project costing R1.5 billion which was primarily focused on the regulatory compliance status of the three manufacturing facilities situated in Gauteng.



The High Volume Liquids facility situated in Clayville is a state of the art and highly automated factory primarily producing liquids and effervescent formulations.



The tablet and capsule facility situated at Wadeville is focused on the manufacture of antiretroviral medicines which are supplied to the public sector through the tender system.

The Critical Care facility situated at Aeroton produces intravenous fluids, blood bags, renal dialysis products and large- and small-volume parenterals.



Distribution Investment:

Adcock Ingram has invested in a state-of-the-art distribution system, designed to distribute the company's products as well as those of its contracted partners, direct to all customers.


Send e-mail to for any enquiries or see Contact Details for phone numbers
Home   •   Terms & conditions   •   PAIA   •   Privacy Policy   •   Security Notice   •   Contact Details
Market Statistics are calculated by Sharenet and are therefore not the official JSE Market Statistics. The calculation/derivation may include underlying JSE data.
© 2018 SHARENET (PTY) Ltd, Cape Town, South Africa
Best in 800x600 with IE6 or Mozilla Firefox